Eirgenix Inc. and Subsidiaries

Consolidated Financial Statements and Independent Auditor's Review Report

For the Three Months Ended March 31, 2026 and 2025

For the convenience of readers and for information purpose only, the auditors' report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors' report and financial statements shall prevail.

INDEPENDENT AUDITORS' REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of EirGenix Inc.

Introduction

We have reviewed the accompanying consolidated balance sheets of EirGenix Inc. and subsidiaries (the "Group") as at March 31, 2026 and 2025, and the related consolidated statements of comprehensive income, of changes in equity and of cash flows for the three months then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of review

We conducted our reviews in accordance with the Standard on Review Engagements 2410, "Review of Financial Information Performed by the Independent Auditor of the Entity" of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of EirGenix Inc. and subsidiaries as at March 31, 2026 and 2025, and of its consolidated financial performance and its consolidated cash flows for the three months then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting" that came into effect as endorsed by the Financial Supervisory Commission.

Yang, Huei-Tzu　　Yen, Yu-Fang

For and on behalf of PricewaterhouseCoopers, Taiwan

May 12, 2026

The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2026, DECEMBER 31, 2025, AND MARCH 31, 2025
(Expressed in thousands of New Taiwan dollars)

			March 31, 2026		December 31, 2025		March 31, 2025	
	Assets	Notes	Amount	%	Amount	%	Amount	%
	Current assets							
1100	Cash and cash equivalents	6(1)	$ 3,257,763	30	$ 3,526,312	32	$ 3,792,791	35
1140	Current contract assets	6(20) and 7	178,191	2	171,144	2	302,105	3
1150	Notes receivable, net	6(4)	128	-	137	-	173	-
1170	Accounts receivable, net	6(4)	42,213	-	114,015	1	234,080	2
1180	Accounts receivable, net - related parties	7	533	-	-	-	226	-
1200	Other receivables		72,074	1	131,994	1	37,153	1
1220	Current income tax assets		27,011	-	24,786	-	29,734	-
130X	Inventories	6(5)	521,764	5	492,872	5	587,661	6
1410	Prepayments	6(6)	88,691	1	82,947	1	243,611	2
11XX	**Total current assets**		4,188,368	39	4,544,207	42	5,227,534	49
	Non-current assets							
1510	Non-current financial assets at fair value through profit or loss	6(2) and 7	115,110	1	148,058	1	116,210	1
1517	Non-current financial assets at fair value through other comprehensive income	6(7)	318,547	3	290,886	3	249,593	2
1535	Non-current financial assets at amortized cost	6(3) and 8	158,638	2	156,679	1	163,529	2
1600	Property, plant and equipment, net	6(8) and 8	4,802,763	45	4,791,069	44	4,233,993	39
1755	Right-of-use assets	6(9)	496,980	5	503,331	4	525,762	5
1780	Intangible assets	6(10)	475,767	4	436,934	4	19,316	-
1900	Other non-current assets	6(8)(11) and 8	63,184	1	76,875	1	231,921	2
15XX	**Total non-current assets**		6,430,989	61	6,403,832	58	5,540,324	51
1XXX	**Total assets**		$ 10,619,357	100	$ 10,948,039	100	$ 10,767,858	100

(Continued)

EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
MARCH 31, 2026, DECEMBER 31, 2025, AND MARCH 31, 2025
(Expressed in thousands of New Taiwan dollars)

			March 31, 2026		December 31, 2025		March 31, 2025	
	Liabilities and equity	Notes	Amount	%	Amount	%	Amount	%
	Current liabilities							
2100	Short-term borrowings	6(12)	$ -	-	$ 300,000	3	$ -	-
2130	Current contract liabilities	6(20) and 7	429,337	4	383,352	3	140,148	2
2170	Accounts payable		169,496	2	98,136	1	96,216	1
2180	Accounts payable - related parties	7	-	-	1,722	-	215	-
2200	Other payables	6(13)	271,145	3	395,119	4	427,737	4
2220	Other payables - related parties	7	12,129	-	12,448	-	10,555	-
2230	Current income tax liabilities		366	-	350	-	657	-
2280	Non-current lease liabilities		21,652	-	22,223	-	23,246	-
2399	Other current liabilities, others		6,586	-	3,988	-	3,981	-
21XX	**Total current liabilities**		910,711	9	1,217,338	11	702,755	7
	Non-current liabilities							
2540	Long-term borrowings	6(14) and 8	1,001,914	9	883,244	8	690,804	6
2570	Deferred tax liabilities		2,392	-	2,252	-	2,134	-
2580	Non-current lease liabilities		495,693	5	500,902	5	519,791	5
2640	Net defined benefit liability, non-current		2,003	-	1,919	-	1,179	-
2670	Other non-current liabilities, others		420	-	420	-	420	-
25XX	**Total non-current liabilities**		1,502,422	14	1,388,737	13	1,214,328	11
2XXX	**Total liabilities**		2,413,133	23	2,606,075	24	1,917,083	18
	Equity							
	Capital	6(17)						
3110	Common stock		3,068,613	29	3,066,002	28	3,062,162	28
3140	Advance receipts for share capital		200	-	458	-	1,219	-
	Capital surplus	6(18)						
3200	Capital surplus		6,319,464	59	6,305,226	58	6,959,252	65
	Retained earnings	6(19)						
3350	Accumulated deficit		(885,111)	(8)	(743,310)	(7)	(855,438)	(8)
	Other equity interest							
3400	Other equity interest		8,523	-	19,053	-	(10,955)	-
3500	Treasury shares	6(17)	(305,465)	(3)	(305,465)	(3)	(305,465)	(3)
3XXX	**Total equity**		8,206,224	77	8,341,964	76	8,850,775	82
	Significant contingent liabilities and unrecognized contract commitments	9						
3X2X	**Total liabilities and equity**		$ 10,619,357	100	$ 10,948,039	100	$ 10,767,858	100

The accompanying notes are an integral part of these consolidated financial statements.

EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(Expressed in thousands of New Taiwan dollars, except for loss per share in New Taiwan dollars)

			January 1 to March 31			
			2026		2025	
	Item	Notes	Amount	%	Amount	%
4000	Operating revenue	6(20) and 7	$ 308,435	100	$ 181,923	100
5000	Operating costs	6(5)(10)(25) and 7	(243,479)	(79)	(164,763)	(90)
5900	Gross profit		64,956	21	17,160	10
	Operating expenses	6(10)(25) and 7				
6100	Selling and marketing expenses		(15,566)	(5)	(15,896)	(9)
6200	General and administrative expenses		(72,926)	(24)	(57,854)	(32)
6300	Research and development expenses		(203,831)	(66)	(179,647)	(99)
6450	Expected credit impairment gain	12(2)	20,127	7	13,417	8
6000	Total operating expenses		(272,196)	(88)	(239,980)	(132)
6900	Net operating loss		(207,240)	(67)	(222,820)	(122)
	Non-operating income and expenses					
7100	Interest income	6(3)(4)(21)	26,571	9	31,600	17
7010	Other income	6(22)	141	-	449	-
7020	Other gains and losses	6(2)(23)	40,866	13	35,869	20
7050	Finance costs	6(8)(9)(24)	(2,174)	(1)	(1,835)	(1)
7000	Total non-operating income and expenses		65,404	21	66,083	36
7900	**Loss before income tax**		(141,836)	(46)	(156,737)	(86)
7950	Income tax	6(26)	(406)	-	(357)	(1)
8200	**Net loss**		($ 142,242)	(46)	($ 157,094)	(87)
	Other comprehensive income, net					
	Components of other comprehensive income that will not be reclassified to profit or loss					
8316	Unrealized valuation gain (loss) from investments in equity instruments measured at fair value through other comprehensive income	6(7)	($ 3,653)	(1)	($ 13,532)	(7)
8310	Total of components of other comprehensive income that will not be reclassified to profit or loss		(3,653)	(1)	(13,532)	(7)
	Components of other comprehensive income that will be reclassified to profit or loss					
8361	Exchange differences on translation of foreign financial statements		(70)	-	565	-
8399	Income tax relating to items that may be reclassified to profit or loss	6(26)	14	-	(113)	-
8360	Total of components of other comprehensive income that will be reclassified to profit or loss		(56)	-	452	-
8300	**Other comprehensive income, net**		($ 3,709)	(1)	($ 13,080)	(7)
8500	**Total comprehensive income (loss)**		($ 145,951)	(47)	($ 170,174)	(94)
	Loss per share	6(27)				
9750	Basic and diluted loss per share		($ 0.47)		($ 0.52)	

The accompanying notes are an integral part of these consolidated financial statements.

EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(Expressed in thousands of New Taiwan dollars)

		Equity attributable to owners of the parent										
			Capital surplus					Other equity interest				
	Notes	Common stock	Additional paid-in capital	Employee stock options	Restricted stocks for employees	Capital surplus, others	Accumulated deficit	Exchange differences on translation of foreign financial statements	Unrealized valuation gain (loss) on financial assets at fair value through other comprehensive income	Unearned compensation	Treasury shares	Total
2025												
Balance at January 1, 2025		$ 3,062,492	$ 6,685,974	$ 208,340	$ 52,127	$ 8,448	($ 698,344)	$ 162	$ 18,099	($ 18,031)	($ 61,010)	$ 9,258,257
Net loss		-	-	-	-	-	(157,094)	-	-	-	-	(157,094)
Other comprehensive income (loss) for the period	6(7)	-	-	-	-	-	-	452	(13,532)	-	-	(13,080)
Total comprehensive income (loss)		-	-	-	-	-	(157,094)	452	(13,532)	-	-	(170,174)
Compensation costs of share-based payments	6(16)	-	-	1,989	-	-	-	-	-	1,895	-	3,884
Employee stock options exercised	6(16)(17)	889	3,928	(1,554)	-	-	-	-	-	-	-	3,263
Employee stock options expired	6(16)	-	-	(5,227)	-	5,227	-	-	-	-	-	-
Restricted stocks vested		-	1,293	-	(1,293)	-	-	-	-	-	-	-
Repurchase of treasury shares	6(17)	-	-	-	-	-	-	-	-	-	(244,455)	(244,455)
Balance at March 31, 2025		$ 3,063,381	$ 6,691,195	$ 203,548	$ 50,834	$ 13,675	($ 855,438)	$ 614	$ 4,567	($ 16,136)	($ 305,465)	$ 8,850,775
2026												
Balance at January 1, 2026		$ 3,066,460	$ 6,038,105	$ 207,523	$ 41,647	$ 17,951	($ 743,310)	$ 837	$ 27,530	($ 9,314)	($ 305,465)	$ 8,341,964
Net loss		-	-	-	-	-	(142,242)	-	-	-	-	(142,242)
Other comprehensive income (loss) for the period	6(7)	-	-	-	-	-	-	(56)	(3,653)	-	-	(3,709)
Total comprehensive income (loss)		-	-	-	-	-	(142,242)	(56)	(3,653)	-	-	(145,951)
Compensation costs of share-based payments	6(16)	-	-	2,848	-	-	-	-	-	7,071	-	9,919
Employee stock options exercised	6(16)(17)	100	213	(21)	-	-	-	-	-	-	-	292
Issuance of restricted stocks for employees	6(16)(17)	2,360	-	-	11,091	-	-	-	-	(13,451)	-	-
Redemption of restricted stocks for employees	6(16)(17)	(107)	-	-	107	-	-	-	-	-	-	-
Restricted stocks vested		-	1,547	-	(1,547)	-	-	-	-	-	-	-
Disposal of equity instruments measured at fair value through other comprehensive income	6(7)	-	-	-	-	-	441	-	(441)	-	-	-
Balance at March 31, 2026		$ 3,068,813	$ 6,039,865	$ 210,350	$ 51,298	$ 17,951	($ 885,111)	$ 781	$ 23,436	($ 15,694)	($ 305,465)	$ 8,206,224

The accompanying notes are an integral part of these consolidated financial statements.

EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(Expressed in thousands of New Taiwan dollars)

	Notes	January 1 to March 31 2026	2025
Cash flows from operating activities			
Net loss before tax		($ 141,836)	($ 156,737)
Adjustments			
Reconcile profit item			
Depreciation expense	6(8)(9)(25)	58,598	58,012
Amortization expense	6(10)(25)	7,254	2,039
Net loss on financial assets measured at fair value through profit or loss	6(2)(23)	6,634	932
Interest expense	6(24)	2,174	1,835
Interest income	6(21)	(26,571)	(31,600)
Compensation costs of share-based payments	6(16)(25)	9,919	3,884
Reversal gain of expected credit impairment loss	12(2)	(20,127)	(13,417)
Unrealized foreign exchange gain		(2,093)	-
Changes in operating assets and liabilities			
Net changes in operating assets			
Contract assets		(7,047)	84,309
Notes receivable, net		9	(123)
Accounts receivable, net		91,929	(110,541)
Accounts receivable – related parties		(533)	2,874
Other receivables		62,378	183
Inventories		(28,892)	(35,573)
Prepayments		(5,744)	(2,096)
Net changes in operating liabilities			
Contract liabilities		45,985	93,972
Accounts payable		71,360	8,929
Accounts payable – related parties		(1,722)	215
Other payables		(80,733)	(42,717)
Other payables – related parties		(319)	2,936
Other current liabilities, others		2,598	784
Net defined benefit liability, non-current		84	48
Cash generated from (used in) operations		43,305	(131,852)
Interest received		24,247	28,668
Interest paid		(7,294)	(5,388)
Income tax paid		(2,459)	(3,182)
Net cash generated from (used in) operating activities		57,799	(111,754)

(Continued)

EIRGENIX INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(Expressed in thousands of New Taiwan dollars)

	Notes	January 1 to March 31 2026	2025
Cash flows from investing activities			
Acquisition of financial assets at fair value through profit or loss	6(2) and 7	($ 5,681)	($ 15,000)
Disposal of financial assets at fair value through other comprehensive income	6(7) and 12(3)	682	-
Acquisition of financial assets at amortized cost		-	(34,341)
Proceeds from disposal of financial assets at amortized cost		-	500,000
Acquisition of property, plant and equipment	6(8)(28)	(53,532)	(416,289)
Acquisition of intangible assets	6(10)(28)	(84,061)	(3,409)
Increase in guarantee deposits paid (presented as "other non-current assets")		-	(17,316)
Decrease in guarantee deposits paid (presented as "other non-current assets")		17,228	-
Recovery of prepayment for investments (presented as "other non-current assets")		-	(33,080)
Increase in prepayments for business facilities (presented as "other non-current assets")	6(8)	(14,103)	(51,594)
Decrease (increase) in other non-current assets		20	(2)
Net cash used in investing activities		(139,447)	(71,031)
Cash flows from financing activities			
Proceeds from short-term borrowings	6(29)	330,000	-
Repayments of short-term borrowings	6(29)	(630,000)	-
Proceeds from long-term borrowings	6(29)	118,670	145,970
Repayments of long-term borrowings	6(29)	-	(20,563)
Repayments of the principal portion of lease liabilities	6(29)	(5,780)	(7,387)
Employee stock options exercised		292	3,263
Repurchase of treasury shares		-	(244,455)
Net cash used in financing activities		(186,818)	(123,172)
Effect of exchange rate		(83)	1,164
Net decrease in cash and cash equivalents		(268,549)	(304,793)
Cash and cash equivalents at beginning of period		3,526,312	4,097,584
Cash and cash equivalents at end of period		$ 3,257,763	$ 3,792,791

The accompanying notes are an integral part of these consolidated financial statements.

EIRGENIX INC. AND SUBSIDIARIES
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025
(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. History and Organization

(1) EirGenix Inc. (hereinafter referred to as "the Company") was a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) in December 2012. In April 2013, the Company obtained all key technologies from the biopharmaceutical pilot plant originally owned by the Development Center for Biotechnology, thereby taking over its complete core competencies. The Company and its subsidiaries (hereinafter collectively referred to as "the Group") are primarily engaged in the research and development (R&D) of biosimilars and new drugs, as well as providing biopharmaceutical contract development and manufacturing services, which included cell line construction platforms, process development platforms, analytical science and protein identification. Additionally, the Company has two PIC/S GMP facilities certified by the Taiwan Food and Drug Administration (TFDA), one for mammalian cells and one for microbial, to provide clinical trial drug and commercial drug production, and product sales.

(2) The shares of the Company have been listed on the Taipei Exchange since June 28, 2019, and have been transferred to the Taiwan Stock Exchange for listing and trading since July 21, 2025.

2. Authorization Date and Procedures for Issuance of Financial Statements

These consolidated financial statements were authorized for issuance by the Board of Directors on May 12, 2026.

3. Application of New, Amended and Revised Standards and Interpretations

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards ("IFRS®") Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission ("FSC")

The table below lists the newly issued, amended and revised standards and interpretations of IFRS Accounting Standards that are applicable in 2026 as endorsed and issued by the FSC:

New, Revised or Amended Standards and Interpretations	Effective date by International Accounting Standards Board ("IASB")
Amendments to IFRS 9 and IFRS 7, "Amendments to the Classification and Measurement of Financial Instruments"	January 1, 2026
Amendments to IFRS 9 and IFRS 7, "Contracts Referencing Nature-dependent Electricity"	January 1, 2026
IFRS 17, "Insurance contracts"	January 1, 2023
Amendments to IFRS 17, "Insurance contracts"	January 1, 2023
Amendments to IFRS 17, "Initial application of IFRS 17 and IFRS 9—Comparative Information"	January 1, 2023
Annual Improvements to IFRS Accounting Standards—Volume 11	January 1, 2026

Except for the following, the above standards and interpretations have no significant impact to the Group's consolidated financial condition and financial performance based on the Group's assessment:

Amendments to IFRS 9 and IFRS 7, "Amendments to the Classification and Measurement of Financial Instruments"

Updates to equity instruments irrevocably designated as at fair value through other comprehensive income (FVOCI) require the disclosure of fair value by class of instrument, rather than for each individual investment. In addition, the amount of fair value gains or losses recognized in other comprehensive income during the reporting period shall be disclosed, separately presenting the amount of fair value gains or losses related to investments derecognized during the reporting period, the amount of fair value gains or losses related to investments still held at the end of the reporting period, and the cumulative gains or losses transferred within equity due to the derecognition of investments during the reporting period.

(2) Effect of new issuances of or amendments to IFRS Accounting Standards that have not yet been endorsed by the FSC

None.

(3) Effect of IFRS Accounting Standards that IASB has issued but not yet endorsed by the FSC

The table below lists the newly issued, amended and revised standards and interpretations issued by IASB but not yet included in the IFRS Accounting Standards endorsed by the FSC:

New, Revised or Amended Standards and Interpretations	Effective date by IASB
Amendments to IFRS 10 and IAS 28, "Sales or Contribution of Assets Between an Investor and its Associate or Joint Venture"	To be determined by IASB
IFRS 18, "Presentation and Disclosure in Financial Statements"	January 1, 2027 (Note)
IFRS 19, "Subsidiaries without Public Accountability: Disclosures"	January 1, 2027
Amendments to IAS 21, "Translation to a Hyperinflationary Currency"	January 1, 2027

Note: The FSC has announced in a press release dated September 25, 2025, that public companies shall adopt IFRS 18 starting from 2028, with the option to early adoption once IFRS 18 is endorsed by the FSC.

Except for IFRS 18 "Presentation and Disclosure in Financial Statements" replacing IAS 1 and updating the framework of the statement of comprehensive income, introducing disclosure of management-defined performance measures, and enhancing the requirements for aggregation and disaggregation of information in both the primary financial statements and the notes, the above standards and interpretations have no significant impact to the Group's consolidated financial condition and financial performance based on the Group's assessment.

4. Summary of Key Accounting Policies

The key accounting policies, except for the compliance statement, basis of preparation, and basis of consolidation, are as follows, and the rest are the same as those in Note 4 to the Consolidated Financial Statements for 2025. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

i. These consolidated financial statements of the Group are prepared in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers and the FSC approved and effective IAS 34 "Interim Financial Reporting".

ii. These consolidated financial statements should be read in conjunction with the 2025 Consolidated Financial Statements.

(2) Basis of preparation

i. Except for the following items, the consolidated financial statements have been prepared under the historical cost convention:

(i) Financial assets (including derivative instruments) at fair value through profit or loss.

(ii) Financial assets at FVOCI.

(iii) Defined benefit liabilities recognized based on the net amount of pension fund assets less present value of defined benefit obligation.

ii. The preparation of financial statements in conformity with the IFRS Accounting Standards, IAS, and Interpretations developed by the International Financial Reporting Interpretations Committee (IFRIC) or the former Standing Interpretations Committee (SIC) (collectively "IFRSs") requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Group's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.

(3) Basis of consolidation

i. The principles for the preparation of these consolidated financial statements are the same as those for the 2025 Consolidated Financial Statements.

ii. Subsidiaries included in the consolidated financial statements:

Name of investor	Name of subsidiary	Business activities	Ownership (%)		
			March 31, 2026	December 31, 2025	March 31, 2025
The Company	EirGenix Europe GmbH	Biopharmaceutical R&D and business development	100	100	100
The Company	EirGenix USA Inc.	Biopharmaceutical commissioned development, manufacturing services, and consultation	100	100	100

iii. Subsidiaries not included in the consolidated financial statements: None.

iv. Adjustments for subsidiaries with different balance sheet dates: None.

v. Significant restrictions: None.

vi. Subsidiaries that have non-controlling interests that are material to the Group: None.

(4) Intangible assets

The Group's accounting policies on intangible assets are summarized below:

i. Computer software

Computer software is stated at cost and amortized on a straight-line basis over its estimated

useful life of 1 to 5 years.

ii. Professional expertise

Professional expertise is stated at cost and amortized on a straight-line basis over its estimated useful life of 2 to 10 years.

iii. Patents

Patents are stated at cost and amortized on a straight-line basis over their estimated useful lives of 13 years.

iv. Internally generated intangible assets – research and development expenses

(i) Research expense is recognized as an expense in the period in which it is incurred.

(ii) Development expense that does not meet the following criteria is recognized as an expense in the period in which it is incurred, while development expense that meets the following criteria is recognized as intangible assets:

A. The technical feasibility of completing the intangible asset so that it will be available for use or sale;

B. Its intention to complete the intangible assets and use or sale it;

C. Its ability to use or sell the intangible asset;

D. Can prove that the intangible asset will generate probable future economic benefits;

E. The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and

F. Its ability to measure reliably the expenditure attributable to the intangible asset during its development.

(iii) Once internally generated intangible assets become available for use, they are amortized on a straight-line basis over their estimated useful life of 20 years.

(5) Employee benefits

The pension cost for the interim period is calculated based on the pension cost rate determined through actuarial assessment at the end of the previous financial year, applicable from the beginning of the year to the end of the period. If there are vital market changes and major reductions, settlements, or other essential one-off events after the end date, adjustments shall be made, and relevant information shall be disclosed in accordance with the aforementioned policies.

(6) Income tax

i. The tax expense for the interim period is calculated by applying the estimated annual average effective tax rate to the profit or loss before tax for the interim period, and relevant information is disclosed in accordance with the aforementioned policies.

ii. When there is a change in the tax rate during the interim period, the Group will recognize the impact of the change in the same period it occurs. For items related to income tax and those recognized outside of profit or loss, the impact will be recorded in other comprehensive income or equity items. If the change affects items recognized in profit or loss, the impact will be recorded in profit or loss.

5. Material Accounting Judgments and Key Sources of Estimation Uncertainty

Reasons and effects of changes in accounting estimates

There were no significant changes during this period. Please refer to Note 5 to the Consolidated Financial Statements for 2025.

6. Details of Significant Accounts

(1) Cash and cash equivalents

	March 31, 2026	December 31, 2025	March 31, 2025
Cash on hand and petty cash	$ 61	$ 61	$ 61
Demand deposits	444,037	1,178,751	220,518
Time deposits	2,813,665	2,347,500	3,572,212
	$ 3,257,763	$ 3,526,312	$ 3,792,791

i. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.

ii. The Group has no cash and cash equivalents pledged to others.

(2) Financial assets at fair value through profit or loss

Item	March 31, 2026	December 31, 2025	March 31, 2025
Non-current items:			
Financial assets mandatorily measured at fair value through profit or loss			
Profit-sharing investment in new drug development	$ 63,990	$ 58,390	$ 58,390
Limited partnership venture capital	51,120	56,588	57,820
Preferred shares	–	33,080	–
	$ 115,110	$ 148,058	$ 116,210

i. The net (loss) gain on financial assets at fair value through profit or loss recognized by the Group for the three months ended March 31, 2026 and 2025 were ($6,634) and ($932),

respectively.

ii. On April 18, 2022, the Group entered into a new drug development profit-sharing agreement for TSY-0110 (EG12043) (the "Product") with FORMOSA PHARMACEUTICALS, INC. (hereinafter referred to as "FORMOSA PHARMACEUTICALS") to replace the original development and manufacturing related cooperation agreement. Raw materials for the Product development stage were provided by the Group at a reasonable market price, and FORMOSA PHARMACEUTICALS was responsible for the R&D of the Product, as well as the implementation of the production and manufacturing of the Product after completing the development of the product. Either party may commercialize the Product in the global market, and each party is entitled to receive 50% licensing interest in any future revenue or interest derived from the development and commercialization of the product. Under the agreement, the Group committed to a total payment of US$30,000 thousand for the licensing interest. This amount will be paid in accordance with the agreement and the development schedule. As of March 31, 2026, the Group has paid US$2,000 thousand.

iii. The Group paid an investment amount of $15,000 to Forward BioT Venture Capital on January 15, 2025, which was accounted for as financial assets at fair value through profit or loss.

iv. On January 12, 2026, the Group paid an investment amount of JPY 28,000 thousand to Daiwa Taiwan-Japan BioVenture Investment Limited Partnership III, which was accounted for as financial assets at fair value through profit or loss.

v. In March 2026, the Group exercised the conversion rights for preferred shares it held in the amount of $31,995. The Group assessed this as a strategic investment; therefore, the shares after conversion were classified as financial assets at FVOCI.

(3) Financial assets at amortized cost

Item	March 31, 2026	December 31, 2025	March 31, 2025
Non-current items:			
Government bonds	$ 30,727	$ 30,861	$ 31,267
Pledged time deposits	9,356	9,356	9,221
Corporate bonds	6,573	6,457	6,824
Privately placed corporate bonds	111,982	110,005	116,217
	$ 158,638	$ 156,679	$ 163,529

i. Amounts recognized in profit or loss in relation to financial assets at amortized cost are listed below:

	Three months ended March 31	
	2026	2025
Interest income	$ 2,112	$ 1,736

ii. Details of the Group's financial assets at amortized cost pledged to others as collateral are provided in Note 8.

iii. Information relating to credit risk of financial assets at amortized cost is provided in Note 12(2). Counterparties of the Group's investments in certificates of deposits, government bonds and corporate bonds are financial institutions and governments with high credit quality. Issuers and guarantors of the private placement corporate bonds are international financial groups with optimal credit ratings. Thus, the risk of counterparty default is expected to be minimal.

(4) Notes and accounts receivable

	March 31, 2026	December 31, 2025	March 31, 2025
Notes receivable	$ 128	$ 137	$ 173
Accounts receivable	$ 66,528	$ 158,457	$ 294,320
Less: Loss allowance	(24,315)	(44,442)	(60,240)
	$ 42,213	$ 114,015	$ 234,080

i. The aging analysis of notes and accounts receivable is as follows:

	March 31, 2026		December 31, 2025		March 31, 2025	
	Notes receivable	Accounts receivable	Notes receivable	Accounts receivable	Notes receivable	Accounts receivable
Not past due	$ 128	$ 37,418	$ 137	$ 110,677	$ 173	$ 221,866
Up to 30 days past due	–	–	–	–	–	–
31–90 days past due	–	1,457	–	3,338	–	8,457
91–180 days past due	–	3,338	–	–	–	–
Over 181 days past due	–	24,315	–	44,442	–	63,997
	$ 128	$ 66,528	$ 137	$ 158,457	$ 173	$ 294,320

The above aging analysis was based on past due date.

ii. As of March 31, 2026, December 31, 2025, and March 31, 2025, the balances of notes

receivable and accounts receivable (including related parties) were generated from customer contracts. In addition, as of January 1, 2025, the receivable balance and loss allowance from contracts with customers were $186,929 and $73,183, respectively.

iii. Interest revenue recognized in profit or loss for the three months ended March 31, 2026 and 2025 were $118 and $297, respectively.

iv. Without considering the collateral or other credit enhancements held, the maximum exposure to credit risk of the Group's notes receivable and accounts receivable (including related parties) as of March 31, 2026, December 31, 2025, and March 31, 2025, were $42,874, $114,152, and $234,479, respectively.

v. The Group did not hold any collateral.

vi. Information relating to credit risk of accounts receivable and notes receivable is provided in Note 12(2).

(5) Inventories

	March 31, 2026		
	Cost	Allowance for valuation loss	Carrying amount
Raw materials	$ 470,848	($ 100,519)	$ 370,329
Work in progress	30,773	–	30,773
Finished goods	127,885	(8,746)	119,139
Merchandise inventory	1,822	(299)	1,523
	$ 631,328	($ 109,564)	$ 521,764

	December 31, 2025		
	Cost	Allowance for valuation loss	Carrying amount
Raw materials	$ 381,741	($ 96,342)	$ 285,399
Work in progress	144,093	–	144,093
Finished goods	61,935	(455)	61,480
Merchandise inventory	2,172	(272)	1,900
	$ 589,941	($ 97,069)	$ 492,872

	March 31, 2025		
	Cost	Allowance for valuation loss	Carrying amount
Raw materials	$ 470,119	($ 99,737)	$ 370,382
Work in progress	73,795	–	73,795
Finished goods	143,737	(1,337)	142,400
Merchandise inventory	1,166	(82)	1,084
	$ 688,817	($ 101,156)	$ 587,661

The cost of inventories recognized by the Group as expense for the period:

	Three months ended March 31	
	2026	2025
Cost of goods used	$ 53,112	$ 30,691
Cost of goods sold	108,827	42,082
Inventory valuation losses	12,495	17,058
Loss on disposal of inventory	5,759	–
	$ 180,193	$ 89,831

(6) Prepayments

	March 31, 2026	December 31, 2025	March 31, 2025
Prepayments for contracted research expense	$ 39,181	$ 39,649	$ 181,489
Excess business tax paid	13,037	13,413	21,742
Prepayments to suppliers	7,425	7,271	8,825
Other prepaid expenses	29,048	22,614	31,555
	$ 88,691	$ 82,947	$ 243,611

(7) Financial assets at FVOCI

	March 31, 2026		
	Cost	Valuation adjustment	Fair value
Emerging and OTC stocks	$ 225,247	$ 21,504	$ 246,751
Non-listed, OTC, and emerging stocks	69,864	1,932	71,796
	$ 295,111	$ 23,436	$ 318,547

	December 31, 2025		
	Cost	Valuation adjustment	Fair value
Emerging and OTC stocks	$ 225,488	$ 26,083	$ 251,571
Non-listed, OTC, and emerging stocks	37,868	1,447	39,315
	$ 263,356	$ 27,530	$ 290,886

	March 31, 2025		
	Cost	Valuation adjustment	Fair value
Emerging and OTC stocks	$ 238,628	$ 2,251	$ 240,879
Non-listed, OTC, and emerging stocks	6,398	2,316	8,714
	$ 245,026	$ 4,567	$ 249,593

i. The Group has elected to classify its strategic equity investments as financial assets at FVOCI. The fair value of these investments as of March 31, 2026, December 31, 2025, and March 31, 2025, were $318,547, $290,886, and $249,593, respectively.

ii. The Group purchased equity instruments for the three months ended March 31, 2026 and 2025, and the investment amounts were both $0. For the reclassification from financial assets at fair value through profit or loss, please refer to Note 6(2)v.

iii. The Group sold emerging and OTC stock investments with a fair value of $682 for the three months ended March 31, 2026, resulting in a cumulative disposal gain of $441.

For the three months ended March 31, 2025: None.

iv. Amounts recognized in comprehensive income in relation to financial assets measured at FVOCI are listed below:

	Three months ended March 31	
	2026	2025
Equity instruments at FVOCI		
Fair value change recognized in other comprehensive (loss) income	($ 3,653)	($ 13,532)
Accumulated gains reclassified as retained earnings due to derecognition	$ 441	$ -

(8) Property, plant and equipment and prepayments for business facilities

	2026							
	Machinery and equipment	Office equipment	Buildings and structures	Leasehold improvements	Other equipment	Construction in progress and equipment to be inspected	Total	Prepayments for business facilities (presented as "other non-current assets")
January 1								
Cost	$ 1,721,209	$ 74,626	$ 1,994,789	$ 56,134	$ 39,269	$ 2,059,588	$ 5,945,615	$ 2,987
Accumulated depreciation	(590,704)	(43,030)	(475,597)	(25,730)	(19,485)	–	(1,154,546)	–
	$ 1,130,505	$ 31,596	$ 1,519,192	$ 30,404	$ 19,784	$ 2,059,588	$ 4,791,069	$ 2,987
January 1	$ 1,130,505	$ 31,596	$ 1,519,192	$ 30,404	$ 19,784	$ 2,059,588	$ 4,791,069	$ 2,987
Additions	8,011	939	1,037	–	537	41,418	51,942	14,103
Reclassifications	28,392	–	–	–	–	(28,392)	–	–
Transfers from other non-current assets	46	–	–	–	–	12,474	12,520	(12,520)
Depreciation expense	(31,637)	(2,397)	(16,227)	(1,225)	(1,281)		(52,767)	–
Net exchange differences	–	(1)	–	–	–	–	(1)	–
March 31	$ 1,135,317	$ 30,137	$ 1,504,002	$ 29,179	$ 19,040	$ 2,085,088	$ 4,802,763	$ 4,570
March 31								
Cost	$ 1,740,162	$ 73,356	$ 1,995,826	$ 51,797	$ 38,548	$ 2,085,088	$ 5,984,777	$ 4,570
Accumulated depreciation	(604,845)	(43,219)	(491,824)	(22,618)	(19,508)	–	(1,182,014)	–
	$ 1,135,317	$ 30,137	$ 1,504,002	$ 29,179	$ 19,040	$ 2,085,088	$ 4,802,763	$ 4,570

2025

	Machinery and equipment	Office equipment	Buildings and structures	Leasehold improvements	Other equipment	Construction in progress and equipment to be inspected	Total	Prepayments for business facilities (presented as "other non-current assets")
January 1								
Cost	$ 1,684,447	$ 81,550	$ 1,988,723	$ 54,890	$ 38,273	$ 1,081,670	$ 4,929,553	$ 134,509
Accumulated depreciation	(521,217)	(47,150)	(414,868)	(20,385)	(19,847)	–	(1,023,467)	–
	$ 1,163,230	$ 34,400	$ 1,573,855	$ 34,505	$ 18,426	$ 1,081,670	$ 3,906,086	$ 134,509
January 1	$ 1,163,230	$ 34,400	$ 1,573,855	$ 34,505	$ 18,426	$ 1,081,670	$ 3,906,086	$ 134,509
Additions	8,725	913	126	–	279	311,875	321,918	51,594
Reclassifications	660	63	–	–	2,009	(2,732)	–	–
Transfers from other non-current assets	1,543	–	–	–	–	55,232	56,775	(56,775)
Depreciation expense	(30,942)	(2,495)	(14,826)	(1,356)	(1,187)	–	(50,806)	–
Net exchange differences	–	20	–	–	–	–	20	–
March 31	$ 1,143,216	$ 32,901	$ 1,559,155	$ 33,149	$ 19,527	$ 1,446,045	$ 4,233,993	$ 129,328
March 31								
Cost	$ 1,657,972	$ 72,650	$ 1,988,849	$ 54,800	$ 37,870	$ 1,446,045	$ 5,258,186	$ 129,328
Accumulated depreciation	(514,756)	(39,749)	(429,694)	(21,651)	(18,343)	–	(1,024,193)	–
	$ 1,143,216	$ 32,901	$ 1,559,155	$ 33,149	$ 19,527	$ 1,446,045	$ 4,233,993	$ 129,328

i. Amount of borrowing costs capitalized as part of property, plant and equipment and the range of the interest rates for such capitalization are as follows:

	Three months ended March 31	
	2026	2025
Amount capitalized	$ 5,199	$ 3,654
Range of interest rates for capitalization	1.72%–2.22%	1.72%–2.22%

ii. Details of the amount of depreciation charge of right-of-use assets and interest expense on lease liabilities capitalized as property, plant and equipment are provided in Note 6(9).

iii. Information regarding the property, plant and equipment that were pledged to others as collateral is provided in Note 8.

(9) Leasing arrangements – lessee

i. The Group leases various assets including land, buildings, machinery and equipment, multifunction printers and fleet vehicles. Rental contracts are typically made for periods of 1 to 20 years. Lease terms are negotiated on an individual basis and may contain a wide range of different terms and conditions. The lease agreements do not impose covenants, but leased assets may not be used as security for borrowing purposes.

ii. The Group leases certain offices, staff quarters, fleet vehicles, and storage units under short-term leases, as the lease terms do not exceed 12 months. The Group also leases low-value assets, which include multifunction printers.

iii. The carrying amounts of right-of-use assets and the recognized depreciation charge are as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
	Carrying amount	Carrying amount	Carrying amount
Land	$ 385,944	$ 389,437	$ 399,916
Buildings	54,805	56,133	61,230
Machinery and equipment	53,684	54,803	60,425
Transportation equipment (fleet vehicles)	641	863	1,530
Office equipment (multifunction printers)	1,906	2,095	2,661
	$ 496,980	$ 503,331	$ 525,762

	Three months ended March 31	
	2026	2025
	Depreciation expense	Depreciation expense
Land	$ 3,493	$ 3,830
Buildings	1,328	2,440
Machinery and equipment	1,119	1,162
Transportation equipment (fleet vehicles)	222	222
Office equipment (multifunction printers)	189	189
	6,351	7,843
Less: Capitalization of depreciation expense	(520)	(637)
	$ 5,831	$ 7,206

iv. For the three months ended March 31, 2026 and 2025, the Group's additions to the right-of-use assets were $0 and $214,521, respectively.

v. The information on profit and loss accounts relating to lease contracts is as follows:

	Three months ended March 31	
	2026	2025
Items affecting profit or loss in the period		
Interest expenses on lease liabilities	$ 2,573	$ 2,038
Expense on short-term lease contracts	3,906	2,856
Expense on leases of low-value assets	6	2
Capitalization of depreciation expense on right-of-use assets	520	637
Capitalization of interest expense on lease liabilities	521	296

vi. The Group's total cash outflow for leases for the three months ended March 31, 2026 and 2025 were $ 12,265 and $12,283, respectively.

vii. Options to extend the lease and options to terminate the lease

The Group, based on the assessment of exercising the extension option, increased the right-of-use assets and lease liabilities by $0, $214,521, and $214,521, respectively as of March 31, 2026, December 31, 2025, and March 31, 2025.

(10) Intangible assets

	Computer software	Professional expertise	Patents	Internally generated intangible assets	Total
January 1, 2026					
Cost	$ 67,801	$ 116,626	$ -	$ 409,388	$ 593,815
Accumulated amortization	(43,263)	(110,206)	–	(3,412)	(156,881)
	$ 24,538	$ 6,420	$ -	$ 405,976	$ 436,934
January 1, 2026	$ 24,538	$ 6,420	$ -	$ 405,976	$ 436,934
Additions, acquired separately	771	316	–	–	1,087
Transfers during the period (Note)	–	–	45,000	–	45,000
Amortization for the period	(1,928)	(209)	–	(5,117)	(7,254)
March 31, 2026	$ 23,381	$ 6,527	$ 45,000	$ 400,859	$ 475,767
March 31, 2026					
Cost	$ 61,014	$ 116,942	$ 45,000	$ 409,388	$ 632,344
Accumulated amortization	(37,633)	(110,415)	–	(8,529)	(156,577)
	$ 23,381	$ 6,527	$ 45,000	$ 400,859	$ 475,767

	Computer software	Professional expertise	Total
January 1, 2025			
Cost	$ 50,071	$ 116,626	$ 166,697
Accumulated amortization	(36,369)	(109,213)	(145,582)
	$ 13,702	$ 7,413	$ 21,115
January 1, 2025	$ 13,702	$ 7,413	$ 21,115
Additions	240	–	240
Amortization for the period	(1,791)	(248)	(2,039)
March 31, 2025	$ 12,151	$ 7,165	$ 19,316
March 31, 2025			
Cost	$ 50,311	$ 116,626	$ 166,937
Accumulated amortization	(38,160)	(109,461)	(147,621)
	$ 12,151	$ 7,165	$ 19,316

Note: Transfers during the period were transfers from prepayments for intangible assets (presented as "other non-current assets").

i. Details of amortization of intangible assets are as follows:

	Three months ended March 31	
	2026	2025
Operating costs	$ 6,046	$ 797
General and administrative expenses	55	237
Research and development expenses	1,142	978
Selling and marketing expenses	11	27
	$ 7,254	$ 2,039

ii. The basic information of the professional expertise that is material to the Group is as follows:

(i) In April 2013, the Group acquired professional expertise originally from the cGMP biopharmaceutical pilot plant of the Development Center for Biotechnology, including cell line development, process development, process scale-up, analytical method development and validation, product identification, GMP production, and stability testing, etc., with a total price of $92,483.

(ii) In July 2013, the Group acquired professional expertise on Herceptin from FORMOSA PHARMACEUTICALS, INC. with a total price of $7,143.

(iii) In July 2013, the Group acquired commercial authorization of recombinant protein cell line from Life Technologies Corporation, with a total price of $7,485.

(iv) In September 2023, the Group obtained an authorization from American Type Culture Collection for the detection of cancer cell line, which can be applied on the commercial implementation of the marketing and manufacturing of subsequent cancer drug products, with a total price of $8,159.

iii. The biosimilar product, EG1206A developed by the Group has completed Phase I clinical trials, with data analysis results of primary endpoints meeting bioequivalence standards. The Group considers that the relevant CMC (Chemistry, Manufacturing, and Controls) and PK (Pharmacokinetics) data are sufficient to demonstrate high similarity between EG1206A and its reference medicinal product, thereby providing predictability over potential outcomes of subsequent clinical trials and the necessity of additional testing, the Company has determined the appropriate timing for capitalization based on a comprehensive assessment and reference to regulatory approval records for biosimilars with similar indications. The Group has assessed that the EG1206A product has already met the capitalization criteria for the development stage of its internal plan; therefore, all necessary directly attributable costs within the relevant development expenses should be recognized as internally generated intangible assets.

(11) Other non-current assets

	March 31, 2026	December 31, 2025	March 31, 2025
Current prepayments for investments	$ -	$ -	$ 33,080
Prepayments for business facilities	4,570	2,987	129,328
Guarantee deposits paid (Note)	9,310	26,538	56,414
Prepayments for intangible assets	49,203	47,229	12,956
Other assets, others	101	121	143
	$ 63,184	$ 76,875	$ 231,921

Note: For information on the pledging of guarantee deposits paid, please refer to Note 8.

(12) Short-term borrowings

As of March 31, 2026 and 2025: None.

Type of borrowings	December 31, 2025	Interest rate range	Collateral
Bank loan			
Loans on credit	$ 300,000	1.90%	None

Interest expense recognized in profit or loss for the three months ended March 31, 2026 and 2025, were $122 and $93, respectively.

(13) Other payables

	March 31, 2026	December 31, 2025	March 31, 2025
Payables for construction and equipment	$ 36,475	$ 43,784	$ 205,784
Salaries and bonuses payable	79,842	116,840	74,579
Service fees payable	34,889	63,844	54,202
Payables for materials consumed	13,104	22,587	10,281
Payables for repair and maintenance expense	42,137	35,057	35,295
Payables for intangible assets	9,000	45,000	–
Others	55,698	68,007	47,596
	$ 271,145	$ 395,119	$ 427,737

(14) Long-term borrowings

Type of borrowings	Borrowing period and repayment term	Interest rate range	Collateral	March 31, 2026
Long-term bank loan				
Loans on credit	Interest is paid monthly from February 15, 2022, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.2200%	None	$ 37,912
"	Interest is paid monthly from June 30, 2022, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.2200%	"	77,529
"	Interest is paid monthly from March 25, 2024, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.5750%	"	357,506
Secured borrowings	Interest is paid monthly from July 15, 2024, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	Buildings and structures	72,136
"	Interest is paid monthly from January 15, 2025, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	145,920

"	Interest is paid monthly from April 15, 2025, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	73,390
"	Interest is paid monthly from September 15, 2025, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	118,900
"	Interest is paid monthly from January 15, 2026, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	118,621
				$ 1,001,914

Type of borrowings	Borrowing period and repayment term	Interest rate range	Collateral	December 31, 2025
Long-term bank loan				
Loans on credit	Interest is paid monthly from February 15, 2022, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.2200%	None	$ 37,912
"	Interest is paid monthly from June 30, 2022, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.2200%	"	77,529
"	Interest is paid monthly from March 25, 2024, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.5750%	"	357,506
Secured borrowings	Interest is paid monthly from July 15, 2024, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	Buildings and structures	72,087
"	Interest is paid monthly from January 15, 2025, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	145,920

"	Interest is paid monthly from April 15, 2025, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	73,390
"	Interest is paid monthly from September 15, 2025, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	118,900
				$ 883,244

Type of borrowings	Borrowing period and repayment term	Interest rate range	Collateral	March 31, 2025
Long-term bank loan				
Loans on credit	Interest is paid monthly from February 15, 2022, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.2200%	None	$ 37,912
"	Interest is paid monthly from June 30, 2022, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.0750%	"	77,529
"	Interest is paid monthly from March 25, 2024, to February 15, 2029, and principal will be repaid on the 15th of each month starting from April 2027.	1.9750%–2.0750%	"	357,506
Secured borrowings	Interest is paid monthly from July 15, 2024, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	Buildings and structures	71,937
"	Interest is paid monthly from January 15, 2025, to July 15, 2034, and principal will be repaid on the 15th of each month starting from August 2027.	1.7200%	"	145,920
				$ 690,804

i. Information on the Group's undrawn borrowing facilities is provided in Note 12(2)iii.

ii. The Group entered into a credit agreement with Hua Nan Commercial Bank Ltd. on December 23, 2021, applying for a total credit limit of $714,000, and in conjunction with

the "Action Plan for Accelerated Investment by Domestic Corporations", the government subsidized the bank's 0.5% handling fee.

iii. The Group entered into a credit agreement with Taiwan Business Bank Co., Ltd. on June 27, 2024, applying for a total credit limit of $1,974,000, and in accordance with the "Action Plan for Accelerated Investment by Domestic Corporations", the government subsidized the bank's 0.5% handling fee.

iv. The Group entered into a supplemental agreement with Hua Nan Commercial Bank Ltd. in March 2025 to extend the loans on credit amounting to $472,947, with principal repayments commencing in April 2027.

v. Information about the collateral for the Group's long-term borrowings is provided in Note 8.

(15) Pensions

i. (i) The Company has established a defined benefit retirement plan in accordance with the Labor Standards Act. This plan applies to foreign employees who are not covered by the Labor Pension Act and who continue to be subject to the Labor Standards Act. For employees who meet the retirement criteria, the pension payments are calculated based on years of service and the average salary over the last six months prior to retirement. For years of service within (and including) 15 years, two units are granted for each completed year, while for years of service exceeding 15 years, one unit is granted for each completed year, with a maximum accumulation limit of 45 units. The Company contributes 2% of the total salary on a monthly basis to the pension fund, which is stored in a dedicated account at Bank of Taiwan in the name of the Labor Retirement Fund Supervisory Commission. Furthermore, the Company estimates the balance of the labor retirement reserve account before the end of each fiscal year. If the balance is insufficient to cover the estimated pension amounts for laborers who meet retirement conditions in the following year as calculated above, the Company will make a one-time contribution to cover the shortfall before the end of March of the following year.

(ii) For the three months ended March 31, 2026 and 2025, the pension costs recognized by the Group under the aforementioned pension plan were $94 and $96, respectively.

(iii) The Group's expected contribution to the pension plans for the year ending December 31, 2026 is $40.

ii. (i) The Company has established a defined contribution pension plan in accordance with the Labor Pension Act, applicable to employees of local nationality. The Company contributes to the labor pension system established under the "Labor Pension Act" for employees who choose to apply, by paying no less than 6% of their monthly salary

into the individual accounts of employees at the Labor Insurance Bureau. The payment of employee pension is based on the amount accumulated in the individual pension accounts and the accumulated earnings, and can be received as monthly pension or a lump sum pension payments for the labor pension and employee pension.

(ii) EirGenix Europe GmbH contributed pension under local regulations.

(iii) For the three months ended March 31, 2026 and 2025, the pension costs recognized by the Group under the aforementioned pension plan were $6,229 and $5,386, respectively.

(16) Share-based payments

i. The Group's share-based payment agreements for the three months ended March 31, 2026 and 2025 are as follows:

Type of arrangement	Grant date	Quantity granted (shares in thousands)	Contract period	Vesting conditions
Employee stock options – B	2015.07.01	1,270	10 years	1–4 years' service
"	2016.01.01	270	"	"
Employee stock options – C	2016.05.05	100	10 years	2–4 years' service
Employee stock options – D	2016.10.12	515	10 years	2–4 years' service
Employee stock options – E	2017.12.27	570	10 years	2–4 years' service
"	2018.03.23	175	"	"
Employee stock options – F	2019.01.25	520	10 years	2–4 years' service
"	2019.05.13	285	"	"
Restricted stocks of employees plan – A	2016.11.18	1,660	N/A	Service years and performance conditions
"	2017.08.08	257	"	"
Employee stock options – G	2019.11.12	960	10 years	2–4 years' service
"	2020.04.15	775	"	"
"	2020.08.12	205	"	"
Restricted stocks of employees plan – B	2020.05.13	455	N/A	0.25–3 years' service
"	2020.12.10	144	"	"
Restricted stocks of employees plan – D	2020.08.14	905	N/A	Performance conditions
"	2020.12.10	94	"	"
Employee stock options – H	2020.12.23	830	10 years	2–4 years' service
"	2021.05.12	315	"	"
"	2021.08.12	505	"	"
"	2021.10.01	1,185	"	"

Type of arrangement	Grant date	Quantity granted (shares in thousands)	Contract period	Vesting conditions
Restricted stocks of employees plan – E	2021.10.15	613	N/A	Performance conditions
"	2022.01.10	184	"	"
"	2022.09.08	190	"	"
Restricted stocks of employees plan – F	2021.10.15	340	N/A	Performance conditions
Employee stock options – I	2022.03.22	160	10 years	2–4 years' service
"	2022.05.12	225	"	"
"	2022.08.11	685	"	"
"	2022.09.08	510	"	"
Restricted stocks of employees plan – G	2022.09.08	63	N/A	Performance conditions
"	2022.11.08	195	"	"
"	2023.03.10	6	"	"
"	2023.11.09	325	"	"
Employee stock options – J	2022.11.08	615	10 years	2–4 years' service
"	2023.03.10	1,105	"	"
"	2023.05.10	255	"	"
"	2023.08.08	225	"	"
"	2023.12.22	270	"	"
"	2024.05.09	225	"	"
Restricted stocks of employees plan – H	2023.11.09	826	N/A	Performance conditions
Restricted stocks of employees plan – I	2023.12.22	26	N/A	Performance conditions
Restricted stocks of employees plan – J	2024.11.12	402	N/A	Performance conditions
"	2025.11.12	409	N/A	Performance conditions
"	2026.03.09	236	N/A	Performance conditions

(i) The restricted stocks for employees issued by the Group cannot be transferred during the vesting period. However, voting right and dividend right are not restricted on these stocks. If employees resign during the vesting period, they are considered not meeting the vesting condition from the date of resignation. The Group will redeem and retire those stocks at the initial issuance price, but employees are not required to return the dividends they have received.

(ii) The aforementioned share-based payment arrangements are equity-settled.

ii. Details of the share-based payment arrangements are as follows:

(i) Employee stock options

	2026		2025	
	No. of options (thousand shares)	Weighted-average exercise price (NTD)	No. of options (thousand shares)	Weighted-average exercise price (NTD)
Options outstanding on January 1	3,907	$25–$146.4	4,686	$15–$146.4
Options forfeited in the period	(125)	85.9–117.5	(215)	71.6–117.5
Options exercised in the period	(10)	29.2	(89)	15–71.6
Options expired in the period	–	–	(90)	71.6–117.5
Options outstanding on March 31	3,772	$25–$146.4	4,292	$15–$146.4
Options exercisable on March 31	2,979		2,340	

(ii) Restricted stocks of employees plan

	2026 (thousand shares)	2025 (thousand shares)
Outstanding on January 1	880	1,314
Number of shares granted in the period	236	–
Number of shares vested in the period	(37)	(28)
Number of shares redeemed in the period	(11)	–
Outstanding on March 31	1,068	1,286

iii. The weighted-average share prices on the exercise dates for stock options exercised during the three months ended March 31, 2026 and 2025 was NT$61.5 and NT$76.7, respectively.

iv. The expiry dates and exercise prices of stock options outstanding at the balance sheet dates are as follows:

			March 31, 2026		December 31, 2025	
Type of arrangement	Issue date approved	Expiry date	No. of shares (shares in thousands)	Exercise price (NTD)	No. of shares (shares in thousands)	Exercise price (NTD)
Employee stock options – B	2015.07.01	2025.06.30	–	$ 15	–	$ 15
"	2016.01.01	2025.12.31	–	20	–	20
Employee stock options – C	2016.05.05	2026.05.04	–	29.2	10	29.2
Employee stock options – D	2016.10.12	2026.10.11	150	29.2	150	29.2
Employee stock options – E	2017.12.27	2027.12.26	30	25	30	25
"	2018.03.23	2028.03.22	–	23.5	–	23.5
Employee stock options – F	2019.01.25	2029.01.24	9	28.7	9	28.7
"	2019.05.13	2029.05.12	80	34.3	80	34.3
Employee stock options – G	2019.11.12	2029.11.11	80	25.2	80	25.2
"	2020.04.15	2030.04.14	20	28.8	20	28.8
"	2020.08.12	2030.08.11	28	51.2	28	51.2
Employee stock options – H	2020.12.23	2030.12.22	127	42.1	127	42.1
"	2021.05.12	2031.05.11	150	146.4	150	146.4
"	2021.08.12	2031.08.11	250	128.4	250	128.4
"	2021.10.01	2031.09.30	490	117.5	540	117.5
Employee stock options – I	2022.03.22	2032.03.21	55	93.5	55	93.5
"	2022.05.12	2032.05.11	78	71.6	78	71.6
"	2022.08.11	2032.08.10	335	85.9	350	85.9
"	2022.09.08	2032.09.07	275	118.5	275	118.5
Employee stock options – J	2022.11.08	2032.11.07	365	103.5	365	103.5
"	2023.03.10	2033.03.09	610	111.5	610	111.5
"	2023.05.10	2033.05.09	205	120	205	120
"	2023.08.08	2033.08.07	115	101.5	140	101.5
"	2023.12.22	2033.12.21	180	100.5	215	100.5
"	2024.05.09	2034.05.08	140	80	140	80

Type of arrangement	Issue date approved	Expiry date	March 31, 2025 No. of shares (shares in thousands)	March 31, 2025 Exercise price (NTD)
Employee stock options – B	2015.07.01	2025.06.30	36	$ 15
"	2016.01.01	2025.12.31	25	20
Employee stock options – C	2016.05.05	2026.05.04	10	29.2
Employee stock options – D	2016.10.12	2026.10.11	150	29.2
Employee stock options – E	2017.12.27	2027.12.26	37	25
"	2018.03.23	2028.03.22	8	23.5
Employee stock options – F	2019.01.25	2029.01.24	19	28.7
"	2019.05.13	2029.05.12	80	34.3
Employee stock options – G	2019.11.12	2029.11.11	80	25.2
"	2020.04.15	2030.04.14	26	28.8
"	2020.08.12	2030.08.11	28	51.2
Employee stock options – H	2020.12.23	2030.12.22	145	42.1
"	2021.05.12	2031.05.11	200	146.4
"	2021.08.12	2031.08.11	250	128.4
"	2021.10.01	2031.09.30	605	117.5
Employee stock options – I	2022.03.22	2032.03.21	55	93.5
"	2022.05.12	2032.05.11	78	71.6
"	2022.08.11	2032.08.10	350	85.9
"	2022.09.08	2032.09.07	295	118.5
Employee stock options – J	2022.11.08	2032.11.07	405	103.5
"	2023.03.10	2033.03.09	660	111.5
"	2023.05.10	2033.05.09	205	120
"	2023.08.08	2033.08.07	190	101.5
"	2023.12.22	2023.12.21	215	100.5
"	2024.05.09	2034.05.08	140	80

v. The Group uses the Black-Scholes option pricing model to estimate the fair value of stock options granted under the employee stock option plans and the restricted stocks for employees plans as part of share-based payments transactions. Relevant information is as follows:

Type of arrangement	Grant date	Quantity granted (shares in thousands)	Share price (NTD)	Exercise price (NTD)	Expected volatility	Expected life	Risk-free interest rate	Fair value per unit (NTD)
Employee stock options – B	2015.07.01	1,270	$14.88	$ 15	36.58–37.13%	5.5–7 years	1.15–1.35%	$5.22–6.01
"	2016.01.01	270	16.03	20	40.11–40.30%	5.5–7 years	0.79–0.90%	4.91–5.76
Employee stock options – C	2016.05.05	100	13.27	29.2	40.75–40.91%	6–7 years	0.70–0.77%	1.86–2.30
Employee stock options – D	2016.10.12	515	21.42	29.2	39.82–39.91%	6–7 years	0.71–0.75%	5.19–5.93
Employee stock options – E	2017.12.27	570	18.07	25	36.97–37.23%	6–7 years	0.74–0.80%	3.81–4.41
"	2018.03.23	175	19.16	23.5	36.87–37.17%	6–7 years	0.79–0.84%	4.71–5.38
Employee stock options – F	2019.01.25	520	21.96	28.7	36.03–36.90%	6–7 years	0.72–0.78%	4.85–5.74
"	2019.05.13	285	25.75	34.3	35.50–36.35%	6–7 years	0.64–0.67%	5.39–6.40
Restricted stocks of employees plan – A	2016.11.18	1,660	22.88	–	–	–	–	22.88
"	2017.08.08	257	19.61	–	–	–	–	19.61
Employee stock options – G	2019.11.12	960	29.05	25.2	26.38%	6–7 years	0.63–0.66%	7.77–8.42
"	2020.04.15	775	33.10	28.8	50.33%	6–7 years	0.47–0.49%	15.56–16.65
"	2020.08.12	205	57.80	51.2	64.08%	6–7 years	0.36–0.38%	33.07–35.18
Restricted stocks of employees plan – B	2020.05.13	455	46.85	–	–	–	–	$46.85
"	2020.12.10	144	48.6	–	–	–	–	48.6
Restricted stocks of employees plan – D	2020.08.14	905	55.7	–	–	–	–	55.7
"	2020.12.10	94	48.6	–	–	–	–	48.6

Type of arrangement	Grant date	Quantity granted (shares in thousands)	Share price (NTD)	Exercise price (NTD)	Expected volatility	Expected life	Risk-free interest rate	Fair value per unit (NTD)
Employee stock options – H	2020.12.23	830	$47.55	$ 42.1	61.28%	6–7 years	0.22–0.26%	$26.15–27.88
"	2021.05.12	315	154.5	146.4	65.02%	6–7 years	0.31–0.35%	89.32–95.02
"	2021.08.12	505	135.5	128.4	67.02%	6–7 years	0.32–0.34%	80.24–85.25
"	2021.10.01	1,185	124.0	117.5	65.78%	6–7 years	0.34–0.38%	72.39–76.99
Restricted stocks of employees plan – E	2021.10.15	613	106.5	–	–	–	–	106.5
"	2022.01.10	184	108.5	–	–	–	–	108.5
"	2022.09.08	190	118.5	–	–	–	–	118.5
Restricted stocks of employees plan – F	2021.10.15	340	106.5	–	–	–	–	106.5
Employee stock options – I	2022.03.22	160	93.5	93.5	62.20%	6–7 years	0.86–0.87%	52.85–56.27
"	2022.05.12	225	71.6	71.6	61.32%	6–7 years	1.22–1.27%	40.37–43.04
"	2022.08.11	685	85.9	85.9	60.04%	6–7 years	1.10–1.14%	47.51–50.67
"	2022.09.08	510	118.5	118.5	60.29%	6–7 years	1.19–1.23%	65.9–70.28
Restricted stocks of employees plan – G	2022.09.08	63	118.5	–	–	–	–	118.5
"	2022.11.08	195	103.5	–	–	–	–	103.5
"	2023.03.10	6	111.5	–	–	–	–	111.5
"	2023.11.09	325	103.0	–	–	–	–	103.0
Employee stock options – J	2022.11.08	615	103.5	103.5	60.00%	6–7 years	1.63–1.70%	57.97–61.88
"	2023.03.10	1,105	111.5	111.5	59.15%	6–7 years	1.12–1.14%	60.98–65.04
"	2023.05.10	255	120.0	120.0	58.70%	6–7 years	1.07–1.09%	65.15–69.50
"	2023.08.08	225	101.5	101.5	57.40%	6–7 years	1.10–1.12%	54.18–57.84
"	2023.12.22	270	100.5	100.5	55.38%	6–7 years	1.18–1.19%	52.26–55.82

Type of arrangement	Grant date	Quantity granted (shares in thousands)	Share price (NTD)	Exercise price (NTD)	Expected volatility	Expected life	Risk-free interest rate	Fair value per unit (NTD)
"	2024.05.09	225	80.0	80.0	53.68%	6–7 years	1.58–1.61%	41.06–43.93
Restricted stocks of employees plan – H	2023.11.09	826	$ 103.0	–	–	–	–	$ 103.0
Restricted stocks of employees plan – I	2023.12.22	26	100.5	–	–	–	–	100.5
Restricted stocks of employees plan – J	2024.11.12	402	89.4	–	–	–	–	89.4
"	2025.11.12	409	67.8	–	–	–	–	67.8
"	2026.03.09	236	57.0	–	–	–	–	57.0

vi. Expenses incurred on share-based payment transactions are shown below:

	Three months ended March 31	
	2026	2025
Employee stock options	$ 2,848	$ 1,989
Restricted stocks for employees	7,071	1,895
	$ 9,919	$ 3,884

(17) Capital

i. As of March 31, 2026, the Company's authorized capital was $4,000,000, consisting of 400,000 thousand ordinary shares (including employee stock option certificates, preferred shares with stock options, or convertible bonds with stock options totaling 20,000 thousand shares), while paid-in capital was $3,068,813 (including $200 for options exercised but not yet registered), consisting of 306,881 thousand shares (including 20 thousand shares for options exercised but not yet registered) with a par value of $10 per share. All proceeds from issued shares have been collected.

Movements in the number of the Company's ordinary shares outstanding are as follows (unit: shares in thousands):

	2026	2025
January 1	301,766	305,408
Exercise of employee stock options	10	89
Vesting of restricted stock for employees	37	–
Repurchase of treasury shares	–	(3,159)
March 31	301,813	302,338

ii. Within the aforementioned paid-in capital, information regarding the exercise of employee stock options for which the registration of change had not yet been completed as of March 31, 2026, December 31, 2025, and March 31, 2025, is as follows:

	March 31, 2026		December 31, 2025		March 31, 2025	
	No. of shares (shares in thousands)	Amount	No. of shares (shares in thousands)	Amount	No. of shares (shares in thousands)	Amount
Capital recognized:						
Employee stock options exercised	20	$ 200	46	$ 458	122	$ 1,219

For details on the exercise of employee stock options of the Company during the three months ended March 31, 2026 and 2025, please refer to Note 6(16).

iii. During the three months ended March 31, 2026 and 2025, as some employees who were granted restricted stocks failed to meet the vesting conditions stipulated in the terms of issuance, the Company, by resolution of the Board of Directors, carried out capital reduction through repurchasing and retiring 11 thousand shares and 0 thousand shares, respectively.

iv. On August 3, 2021, the Company's shareholders resolved to issue 55,000 thousand ordinary shares through private placement. The Board of Directors resolved on October 1, 2021 to set the issuance price per share at $91.5, with a total issuance value of $5,032,500, and the capital increase base date set for October 15, 2021. The registration for change for this capital increase was completed on December 13, 2021. The rights and obligations of the ordinary shares issued through this private placement are the same as those of other issued ordinary shares, except that these shares are subject to transfer restrictions as stipulated by the Securities and Exchange Act, and are only eligible to apply for listing and trading after a three-year lock-up period from the delivery date and completion of public issuance procedures .

v. On May 30, 2024, the Company's shareholders resolved to issue the first tranche of

restricted stock for employees for 2024, totaling 1,400 thousand shares, for no consideration. The terms of issuance for these restricted stocks for employees are in accordance with the regulations. The Board of Directors resolved on November 12, 2024 to issue 402 thousand shares, with the capital increase base date set for November 12, 2024; resolved on November 12, 2025 to issue 409 thousand shares, with the capital increase base date set for November 12, 2025, and resolved on March 9, 2026 to issue 236 thousand shares, with the capital increase base date set for March 9, 2026.

vi. On May 30, 2024, the Company's shareholders resolved to carry out cash capital increase through private placement by issuing ordinary shares not exceeding 30,000 thousand shares, and the private placement may be carried out in three installments as authorized by the shareholders. This private placement was to be conducted in accordance with the Securities and Exchange Act and the Directions for Public Companies Conducting Private Placements of Securities. The Company's Board of Directors resolved on March 12, 2025 to not execute this private placement .

vii. On June 27, 2025, the Company's shareholders resolved to issue the first tranche of restricted stock for employees for 2025, totaling 520 thousand shares, for no consideration. The terms of issuance for these restricted stocks for employees are in accordance with the regulations. As of May 12, 2026, these stocks have not yet been issued.

viii. On June 27, 2025, the Company's shareholders resolved to carry out cash capital increase through private placement by issuing ordinary shares not exceeding 30,000 thousand shares, and the private placement may be carried out in three installments as authorized by the shareholders. This private placement was to be conducted in accordance with the Securities and Exchange Act and the Directions for Public Companies Conducting Private Placements of Securities. The Company's Board of Directors resolved on March 9, 2026 to not execute this private placement .

ix. On March 9, 2026, the Company's Board of Directors resolved to carry out cash capital increase through private placement by issuing ordinary shares not exceeding 30,000 thousand shares, and the private placement may be carried out in three installments as authorized by the shareholders. However, as of May 12, 2026, it has not yet been resolved by the shareholders.

x. On March 9, 2026, the Company's Board of Directors resolved on to issue the first tranche of 2026 restricted stocks for employees for 2026, totaling 1,530 thousand shares of, for no consideration. However, as of May 12, 2026, it has not yet been resolved by the shareholders.

xi. Treasury shares

(i) On December 16, 2024, the Company's Board of Directors resolved at its special

meeting to repurchase an estimated 4,000 thousand shares of the Company, all of which are to be transferred to employees.The scheduled repurchase period was from December 17, 2024 to February 16, 2025. The Company completed the aforementioned share repurchase plan on February 11, 2025, with a total of 4,000 thousand shares repurchased, and the aggregate repurchase price was $305,465.

(ii) Details of the Company's shares held by the Company as of March 31, 2026, December 31, 2025, and March 31, 2025 are as follows:

		March 31, 2026	
Name of company holding shares	Reason for reacquisition	No. of shares (shares in thousands)	Carrying amount
The Company	To be transferred to employees	4,000	$ 305,465

		December 31, 2025	
Name of company holding shares	Reason for reacquisition	No. of shares (shares in thousands)	Carrying amount
The Company	To be transferred to employees	4,000	$ 305,465

		March 31, 2025	
Name of company holding shares	Reason for reacquisition	No. of shares (shares in thousands)	Carrying amount
The Company	To be transferred to employees	4,000	$ 305,465

(iii) Pursuant to the R.O.C. Securities and Exchange Act, the number of shares bought back as treasury shares shall not exceed 10% of the number of the Company’s issued and outstanding shares and the amount bought back shall not exceed the sum of retained earnings, paid-in capital in excess of par value and realized capital surplus.

(iv) Pursuant to the R.O.C. Securities and Exchange Act, the Company’s treasury shares shall not be pledged and not be entitled to shareholder rights before being transferred.

(v) Pursuant to the R.O.C. Securities and Exchange Act, treasury shares repurchased for transfer to employees must be transferred within five years from the date of repurchase. Any shares not transferred within the time limit shall be deemed unissued shares of the Company and shall be canceled through amendment registration. Treasury shares repurchased for purposes of maintaining the Company’s credit rating and the stockholders’ interests should be retired within six months from the date of repurchase through amendment registration.

(18) Capital surplus

Pursuant to the R.O.C. Company Act, capital surplus arising from income derived from the issuance of new shares at a premium and income from endowments received can be used to cover accumulated deficit, or when the Company incurs no loss, it may, issue new shares to its original shareholders in proportion to the number of shares being held by each of them or by cash. In addition, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalized, as mentioned above, should not exceed 10% of the paid-in capital each year. However, capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.

(19) Accumulated deficit

i. Under the Company's Articles of Incorporation, the current year's earnings, if any, shall first be used to pay all taxes and offset prior years' operating losses, and then 10% of the remaining amount shall be set aside as legal reserve. After the provision or reversal of special reserve in accordance with laws or regulations, the appropriation of the remaining earnings, along with the unappropriated earnings of prior years, shall be proposed by the Board of Directors and resolved at shareholders' meetings.

ii. The Company's dividend policy is summarized as follows: The Board of Directors would consider the earnings situation of the current year, capital and financial structure, future operating needs, retained earnings and legal reserve, as well as the market competition when proposing the appropriation of earnings for shareholders' approval on their meetings, and cash dividends shall account for at least 10% of the total dividends distributed.

iii. On June 27, 2025, the Company's shareholders resolved to, regarding the deficit compensation for 2024, offset the entire accumulated deficit of $698,344 with capital surplus. Please refer to the Market Observation Post System (MOPS) website for information regarding the deficit compensation as proposed by the Board of Directors and resolved by the shareholders.

iv. On March 9, 2026, the Company's Board of Directors proposed a deficit compensation plan for 2025, to offset the entire accumulated deficit of $743,310 with capital surplus. However, as of May 12, 2026, it has not yet been resolved by the shareholders. Please refer to the MOPS website for information regarding the deficit compensation as proposed by the Board of Directors.

v. As of March 31, 2026 and 2025, the Company had no distributable earnings.

(20) Operating Revenue

	Three months ended March 31	
	2026	2025
Revenue from contracts with customers	$ 308,435	$ 181,923

i. Disaggregation of revenue

The Group derives revenue from the transfer of services and authorization over time and goods at a point in time in the following major categories:

	Three months ended March 31, 2026			
	Sales of services	Sales of authorization and cooperative development	Sales of goods	Total
Timing of revenue recognition				
At a point in time	$ -	$ -	$ 51,876	$ 51,876
Over time	135,365	51,016	70,178	256,559
	$ 135,365	$ 51,016	$ 122,054	$ 308,435

	Three months ended March 31, 2025			
	Sales of services	Sales of authorization and cooperative development	Sales of goods	Total
Timing of revenue recognition				
At a point in time	$ -	$ -	$ 1,753	$ 1,753
Over time	77,218	94	102,858	180,170
	$ 77,218	$ 94	$ 104,611	$ 181,923

ii. Contract assets and liabilities

(i) The Group has recognized the following contract assets and liabilities related to the revenue from contracts with customers:

	March 31, 2026	December 31, 2025	March 31, 2025	January 1, 2025
Current contract assets:				
Services	$ 76,568	$ 75,893	$ 198,805	$ 274,085
Sales	105,927	99,555	117,577	126,606
Less: Loss allowance	(4,304)	(4,304)	(14,277)	(14,751)
	$ 178,191	$ 171,144	$ 302,105	$ 385,940
Current contract liabilities:				
Services	$ 133,132	$ 43,269	$ 133,884	$ 39,818
Authorization and cooperative development	289,067	340,083	6,264	6,358
Sales	7,138	–	–	–
	$ 429,337	$ 383,352	$ 140,148	$ 46,176

(ii) Revenue recognized that was included in the contract liabilities at the beginning of the period

Revenue recognized that was included in the contract liabilities balance at the beginning of the period	Three months ended March 31, 2026	Three months ended March 31, 2025
Services	$ 28,816	$ 6,699
Authorization and cooperative development	51,016	94
	$ 79,832	$ 6,793

(iii) Unfulfilled long-term contracts

Aggregate amount of the transaction price allocated to long-term technology service contracts and authorization and cooperative development contracts that are partially or fully unsatisfied, and all of the milestone payment as of March 31, 2026 amounted to $4,793,605. The management expects to recognize the amount in the future.

(iv) Information relating to credit risk of contract assets is provided in Note 12(2).

iii. Details on authorization and cooperative development revenue arising from providing drug development, commercialization service and authorizing intellectual property rights of pharmaceutical products to the pharmaceutical factory are as follows:

(i) In April 2019, the Group entered into an EG12014 authorization and cooperative development contract with Sandoz AG. The contract includes an up-front payment, milestone payments at each stage, and profit-sharing royalties on sales of products in the authorized markets in proportion to the ratios specified in the contract. The contract is mainly for providing biosimilars development and commercialization services and authorization of intellectual property rights to customers in authorized

regions. As of March 31, 2026, the Group had collected the aforementioned up-front payment and part of the milestone payments in accordance with the contract terms. The revenue of up-front payment and payments for milestone achieved is recognized based on the satisfaction percentage during the R&D period. If the drug is successfully launched, the supply price based on the supply terms and quantities, and the profit-sharing royalty calculated based on sales could also be collected.

(ii) In November 2025, the Group entered into an EG1206A authorization and cooperative development agreement in the authorized territory with Sandoz AG. The contract includes an upfront payment, milestone payments at each R&D and sales stage, and profit-sharing royalties on sales of products in the authorized markets in proportion to the ratios specified in the contract. The Company is also entitled to potential sales incentive based on market performance. As of March 31, 2026, the Group has collected the aforementioned upfront payment in accordance with the contract terms. The revenue of upfront payment and payments for milestone achieved is recognized based on the satisfaction percentage during the R&D period. If the drug is successfully launched, the supply price based on the supply terms and quantities, and the profit-sharing royalty calculated based on sales could also be collected.

(iii) On March 24, 2026, the Group and its partner Sandoz AG have entered into a settlement and patent license agreement with Genentech and Roche regarding EG1206A pertuzumab biosimilar in the U.S. and Europe.

(iv) The Group recognized sales of authorization and cooperative development of $51,016 and $94 for the the three months ended March 31, 2026 and 2025, respectively.

(v) The USFDA accepted Sandoz AG's application for marketing review of EG12014 in June 2024. Sandoz AG received a complete response letter (CRL) from the USFDA in December 2024, the primary contents of which included:

A. There were no clinical efficacy or safety or biosimilarity deficiencies cited in the CRL.

B. The CRL cites certain drug product deficiencies related to the manufacturing facility identified by the agency during a pre-license inspection of the site by third-party suppliers.

(vi) Sandoz AG submitted a re-submission for the EG12014 Biologics License Application (BLA) to the USFDA in June 2025 using its own lyophilization and fill-finish facility, and received a CRL from the USFDA in December 2025, the primary contents of which included:

A. There were no clinical efficacy or safety or biosimilarity deficiencies cited in the CRL.

B. The CRL cites certain observations regarding drug product manufacturing identified by the USFDA. Satisfactory resolution of the observations is required

before the BLA can be approved.

(vii) The Company received an Establishment Inspection Report (EIR) from the USFDA in January 2023, which indicated that the Company's Zhubei plant had passed the USFDA's pre-marketing drug inspection.

iv. The Company received a letter from the TFDA in April 2023, which indicated that the Company had obtained the domestic active pharmaceutical ingredient "EG12014 Trastuzumab (Trastuzumab)" license and a drug master file number. Subsequently, the Company received an approval letter for the biosimilar "EIRGASUN vial 150 mg" from the Taiwan Ministry of Health and Welfare in May 2023. In September 2023, its enrollment in the National Health Insurance reimbursement system is approved, which became effective from October 1, 2023. The Company received an approval letter for the biosimilar "EIRGASUN vial 420 mg" from the Taiwan Ministry of Health and Welfare in October 2025.

v. The biosimilar, EG12014 Trastuzumab, licensed by the Company to Sandoz AG for sale, has received marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) on November 16, 2023.

(21) Interest income

	Three months ended March 31	
	2026	2025
Interest income from bank deposits	$ 24,341	$ 29,567
Interest income from financial assets measured at amortized cost	2,112	1,736
Other interest income	118	297
	$ 26,571	$ 31,600

(22) Other income

	Three months ended March 31	
	2026	2025
Government grant revenue	$ -	$ 110
Other income, others	141	339
	$ 141	$ 449

(23) Other gains and losses

	Three months ended March 31	
	2026	2025
Foreign exchange gains	$ 47,500	$ 36,801
Losses on financial assets at fair value through profit or loss	(6,634)	(932)
	$ 40,866	$ 35,869

(24) Finance costs

	Three months ended March 31	
	2026	2025
Interest expense on lease liabilities	$ 2,573	$ 2,038
Interest expense on bank borrowings	4,800	3,451
	7,373	5,489
Less: Capitalization of interest expense (Note)	(5,199)	(3,654)
Interest expense	$ 2,174	$ 1,835

Note: Please refer to the explanations in Notes 6(8) and 6(9).

(25) Employee benefits, depreciation and amortization expenses

Function / Nature	January 1 to March 31, 2026			January 1 to March 31, 2025		
	Classified as operating costs	Classified as operating expenses	Total	Classified as operating costs	Classified as operating expenses	Total
Employee benefit expense						
Salary expenses	$ 40,988	$ 96,595	$137,583	$ 32,792	$ 83,906	$116,698
Share-based payments	1,358	8,561	9,919	1,324	2,560	3,884
Labor and health insurance fees	3,801	8,443	12,244	3,219	7,246	10,465
Pension costs	2,050	4,273	6,323	2,144	3,338	5,482
Director remuneration	–	1,255	1,255	–	1,075	1,075
Other personnel expenses	1,576	3,680	5,256	1,317	2,985	4,302
Depreciation expense	27,429	31,169	58,598	26,655	31,357	58,012
Amortization expense	6,046	1,208	7,254	797	1,242	2,039

i. In accordance with the Articles of Incorporation of the Company, if there is a remaining balance after covering accumulated deficit from the current year's profit, 1% to 5% shall be allocated as employees' remuneration (of which no less than 10% of the aforementioned amount shall be distributed to base-level employees) and not more than 3% as directors' remuneration.

ii. The Company has incurred accumulated deficit for the three months ended March 31, 2026 and 2025. Therefore, no accrual for employee compensation and director remuneration is required.

iii. Please refer to the MOPS website for information regarding employee compensation and director remuneration as approved by the Board of Directors and resolved by the shareholders of the Company.

(26) Income tax

i. Income tax expense

(i) Components of income tax expense:

	Three months ended March 31	
	2026	2025
Current income tax:		
Current tax on profits	$ 252	$ 228
Deferred income tax:		
Origination and reversal of temporary differences	154	129
Total deferred income tax	154	129
Income tax	$ 406	$ 357

(ii) The income tax charge relating to components of other comprehensive income is as follows:

	Three months ended March 31	
	2026	2025
Exchange differences on translation of foreign operations	($ 14)	$ 113

ii. The Company's profit-seeking enterprise income tax has been assessed up to 2023 by the tax authorities.

(27) Loss per share

	Three months ended March 31, 2026		
	Amount after tax	Weighted-average number of ordinary shares outstanding (shares in thousands)	Loss per share (NTD)
Basic loss per share			
Net loss	($ 142,242)	301,778	($ 0.47)

	Three months ended March 31, 2025		
	Amount after tax	Weighted-average number of ordinary shares outstanding (shares in thousands)	Loss per share (NTD)
Basic loss per share			
Net loss	($ 157,094)	302,804	($ 0.52)

For the three months ended March 31, 2026 and 2025, the Company incurred a net loss for the period; therefore, diluted loss per share was not calculated.

(28) Supplementary cash flow information

Investing activities with partial cash payments:

	Three months ended March 31	
	2026	2025
Purchase of property, plant and equipment	$ 51,942	$ 321,918
Add: Beginning balance of other payables	43,784	304,446
Less: Ending balance of other payables	(36,475)	(205,784)
Capitalization of depreciation expense on right-of-use assets	(520)	(637)
Capitalization of interest expense	(5,199)	(3,654)
Cash paid during the period	$ 53,532	$ 416,289

	Three months ended March 31	
	2026	2025
Purchase of intangible assets	$ 46,087	$ 240
Add: Ending balance of prepaid intangible assets (Note)	49,203	12,956
Add: Beginning balance of payables for intangible assets	45,000	–
Less: Beginning balance of prepaid intangible assets (Note)	(47,229)	(9,787)
Less: Ending balance of payables for Intangible assets	(9,000)	–
Cash paid during the period	$ 84,061	$ 3,409

Note: Presented as “other non-current assets”.

(29) Changes in liabilities from financing activities

	2026			
	Short-term borrowings	Long-term borrowings (including current portion)	Lease liabilities	Liabilities from financing activities – gross
January 1	$ 300,000	$ 883,244	$ 523,125	$ 1,706,369
Changes in cash flows in financing activities	(300,000)	118,670	(5,780)	(187,110)
March 31	$ -	$ 1,001,914	$ 517,345	$ 1,519,259

	2025		
	Long-term borrowings (including current portion)	Lease liabilities	Liabilities from financing activities – gross
January 1	$ 565,397	$ 335,903	$ 901,300
Changes in cash flows in financing activities	125,407	(7,387)	118,020
Changes in right-of-use assets	–	214,521	214,521
March 31	$ 690,804	$ 543,037	$ 1,233,841

7. Related Party Transactions

(1) Parent and ultimate controlling party

The Group has no ultimate parent company and ultimate controlling party.

(2) Names of related parties and relationship

Names of related parties	Relationship with the Group
FORMOSA LABORATORIES, INC. (FORMOSA LABORATORIES)	Other related party
FORMOSA PHARMACEUTICALS, INC. (FORMOSA PHARMACEUTICALS)	"
TFBS Bioscience Inc.(TFBS Bioscience)	"
Forward BioT Venture Capital(Forward BioT)	"

(3) Significant related party transactions

i. Operating revenue

	Three months ended March 31	
	2026	2025
Sales of goods:		
Other related party	$ 50	$ 351
Sales of services:		
Other related party	15,340	309
	$ 15,390	$ 660

(i) No similar transaction can be compared with for the sales of services of the Group. Prices and terms are determined based on mutual agreements.

(ii) The Group's contract assets recognized in relation to revenue from contracts with customers as of March 31, 2026, December 31, 2025, and March 31, 2025 were all $337; with contract liabilities of $3,360, $8,284 and $492, respectively.

ii. Purchases

	Three months ended March 31	
	2026	2025
Purchases of goods:		
Other related parties	$ -	$ 205

Goods purchased from other related parties are based on normal commercial terms and conditions.

iii. Processing fees (presented as "operating costs")

	Three months ended March 31	
	2026	2025
Other related parties	$ 42	$ -

iv. Service fees (presented as "research and development expenses")

	Three months ended March 31	
	2026	2025
Other related party – FORMOSA LABORATORIES	$ 4,288	$ 3,676

The service fees are mainly for commissioning for biopharmaceutical R&D, with prices and terms agreed upon by both parties.

v. Testing fees (presented as "operating costs")

	Three months ended March 31	
	2026	2025
Other related party – TFBS Bioscience	$ 1,349	$ 4,942
Other related party – FORMOSA LABORATORIES	1,124	200
	$ 2,473	$ 5,142

vi. Receivables from related parties

	March 31, 2026	December 31, 2025	March 31, 2025
Accounts receivable:			
Other related party	$ 533	$ -	$ 226

vii. Payables to related parties

	March 31, 2026	December 31, 2025	March 31, 2025
Accounts payable:			
Other related parties	$ -	$ 1,722	$ 215
Other payables:			
Other related parties	$ 12,129	$ 12,448	$ 10,555

viii. Property transactions

Acquisition of financial assets:

		Three months ended March 31	
		2026	2025
	Accounting item	Acquisition price	Acquisition price
Other related party – Forward BioT	Financial assets at fair value through profit or loss	$ -	$ 15,000

For transaction details of the Group acquiring assets from related parties, please refer to the explanation in Note 6(2)iii.

(4) Information on key management compensation

	Three months ended March 31	
	2026	2025
Salaries and other short-term employee benefits	$ 11,625	$ 9,905
Post-employment benefits	168	159
Share-based payments	4,388	49
	$ 16,181	$ 10,113

8. Pledged Assets

The Group's assets pledged as collateral are detailed below:

	Book value			
Asset item	March 31, 2026	December 31, 2025	March 31, 2025	Purpose
Pledged time deposits (classified as "non-current financial assets at amortized cost")	$ 9,356	$ 9,356	$ 9,221	Note 1
Guarantee deposits paid (classified as "other non-current assets")	$ 9,310	$ 26,538	$ 56,414	Note 2
Property, plant and equipment, net	$ 1,417,915	$ 1,428,381	$ 1,456,879	Note 3
Pledged government bonds (classified as "non-current financial assets at amortized cost")	$ 30,727	$ 30,861	$ 31,267	Note 4

Note 1: Represents land lease deposits and pledged time deposits provided as collateral for customs post-release duty payments.

Note 2: Represents deposits for contracted research agreements, equipment deposits, office deposits, gas meter guarantee deposits, performance guarantee deposits, and customs deferred tax collateral time deposits.

Note 3: Represents facilities for long-term borrowings.

Note 4: Represents investment deposits for the science park.

9. Significant Contingent Liabilities and Unrecognized Contract Commitments

(1) Contingent events

None.

(2) Commitments

i. As of March 31, 2026, December 31, 2025, and March 31, 2025, the remaining amounts to be paid in future for the commissioned research contracts entered into by the Group were $76,182, $62,884, and $808,412, respectively.

ii. As of March 31, 2026, December 31, 2025, and March 31, 2025, the remaining amounts to be paid in future for the purchase of equipment and plant design contracts entered into by the Group were $526,843, $526,828, and $1,161,308, respectively.

iii. To ensure future supply of goods, the Group has entered into a long-term manufacturing consignment contract with a vendor and paid a guarantee deposit of $30,000. As both parties decided to amend the contract and the guaranteed deposit is expected to be returned, the

aforementioned amount was reclassified from other non-current assets to other receivables on December 31, 2025.

iv. In December 2025, the Group entered into a production technology licensing agreement with a foreign biopharmaceutical company, for a total license fee of RMB 63,000 thousand, with subsequent royalty payments to be made at a fixed percentage of net sales generated from the use of such technology over a certain period. As of March 31, 2026, the Group has paid RMB 10,000 thousand.

10. Significant Disaster Losses

None.

11. Significant Events after the Balance Sheet Date

None.

12. Others

(1) Capital management

The Group's objectives when managing capital are to ensure the Group's continued operation as a going concern, to deliver returns for shareholders, and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares, or sell assets to reduce debt.

(2) Financial instruments

i. Financial instruments by category

	March 31, 2026	December 31, 2025	March 31, 2025
Financial assets			
Financial assets at fair value through profit or loss			
Financial assets mandatorily measured at fair value through profit or loss	$ 115,110	$ 148,058	$ 116,210
Financial assets at FVOCI - Designation of equity instrument	$ 318,547	$ 290,886	$ 249,593

Financial assets at amortized cost			
Cash and cash equivalents	$ 3,257,763	$ 3,526,312	$ 3,792,791
Financial assets at amortized cost	158,638	156,679	163,529
Notes receivable	128	137	173
Accounts receivable	42,213	114,015	234,080
Accounts receivable – related parties	533	–	226
Other receivables	72,074	131,994	37,153
Guarantee deposits paid (presented as "other non-current assets")	9,310	26,538	56,414
	$ 3,540,659	$ 3,955,675	$ 4,284,366

	March 31, 2026	December 31, 2025	March 31, 2025
Financial liabilities			
Financial liabilities at amortized cost			
Short-term borrowings	$ -	$ 300,000	$ -
Accounts payable	169,496	98,136	96,216
Accounts payable – related parties	–	1,722	215
Other payables	271,145	395,119	427,737
Other payables – related parties	12,129	12,448	10,555
Long-term borrowings	1,001,914	883,244	690,804
Guarantee deposits received (presented as "other current and non-current liabilities, others")	420	420	420
	$ 1,455,104	$ 1,691,089	$ 1,225,947
Lease liabilities	$ 517,345	$ 523,125	$ 543,037

ii. Risk management policies

There were no significant changes during this period. Please refer to Note 12 to the Consolidated Financial Statements for 2025.

iii. Nature and extent of significant financial risks

(i) Market risk

A. Exchange rate risk

(A) The Group operates internationally and is exposed to exchange rate risk arising from various currency exposures, primarily the USD, EUR, GBP, and

JPY. Exchange rate risk arises from future commercial transactions and recognized assets and liabilities.

(B) The Group's management has set up a policy to require companies within the Group to manage their exchange rate risk against their functional currencies. Companies within the Group are required to hedge their entire exchange rate risk through the Group's Treasury.

(C) The Group's businesses involve some non-functional currency operations (the Group's functional currency: NTD; subsidiaries' functional currencies: USD and EUR). The information on assets and liabilities denominated in foreign currencies that would be significantly affected by the exchange rate fluctuations is as follows:

	March 31, 2026		
	Foreign currency (thousand)	Exchange rate	Carrying amount (NTD)
Financial assets			
Monetary items			
USD:NTD	$ 77,400	32.00	$ 2,476,800
EUR:NTD	1,593	36.71	58,479
GBP:NTD	96	42.27	4,058
JPY:NTD	50,099	0.20	10,020
Financial liabilities			
Monetary items			
USD:NTD	$ 281	32.00	$ 8,992
EUR:NTD	354	36.71	12,995
GBP:NTD	52	42.27	2,198
JPY:NTD	759	0.20	152

	December 31, 2025		
	Foreign currency (thousand)	Exchange rate	Carrying amount (NTD)
Financial assets			
Monetary items			
USD:NTD	$ 76,423	31.43	$ 2,401,975
EUR:NTD	1,074	36.90	39,631
GBP:NTD	65	42.33	2,751
JPY:NTD	58,510	0.20	11,702
Financial liabilities			
Monetary items			
USD:NTD	$ 913	31.43	$ 28,696
EUR:NTD	2,118	36.90	78,154
GBP:NTD	33	42.33	1,397
JPY:NTD	42,375	0.20	8,475

	March 31, 2025		
	Foreign currency (thousand)	Exchange rate	Carrying amount (NTD)
Financial assets			
Monetary items			
USD:NTD	$ 61,430	33.21	$ 2,040,090
EUR:NTD	424	35.97	15,251
GBP:NTD	79	43.05	3,401
JPY:NTD	16,986	0.22	3,736
Financial liabilities			
Monetary items			
USD:NTD	$ 173	33.21	$ 5,745
EUR:NTD	1,141	35.97	41,042
GBP:NTD	46	43.05	1,980

(D) Analysis of foreign currency market risk arising from significant foreign exchange fluctuation:

	Three months ended March 31, 2026		
	Sensitivity analysis		
	Degree of fluctuation	Effect on profit or loss	Effect on other comprehensive income
Financial assets			
Monetary items			
USD:NTD	1%	$ 24,768	$ -
EUR:NTD	1%	517	68
GBP:NTD	1%	41	–
JPY:NTD	1%	100	–
Financial liabilities			
Monetary items			
USD:NTD	1%	$ 90	$ -
EUR:NTD	1%	130	–
GBP:NTD	1%	22	–
JPY:NTD	1%	2	–

	Three months ended March 31, 2025		
	Sensitivity analysis		
	Degree of fluctuation	Effect on profit or loss	Effect on other comprehensive income
Financial assets			
Monetary items			
USD:NTD	1%	$ 20,401	$ -
EUR:NTD	1%	86	67
GBP:NTD	1%	34	–
JPY:NTD	1%	37	–
Financial liabilities			
Monetary items			
USD:NTD	1%	$ 57	$ -
EUR:NTD	1%	410	–
GBP:NTD	1%	20	–

(E) The aggregate amount of all foreign exchange gains (including realized and unrealized) recognized by the Group for the three months ended March 31, 2026 and 2025, due to the significant impact of exchange rate fluctuations on monetary items, was $47,500 and $36,801, respectively.

B. Price risk

(A) The Group's equity instruments exposed to price risk comprise financial assets held at fair value through profit or loss and financial assets held at FVOCI. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio. Diversification of the portfolio is carried out in accordance with the limits set by the Group.

(B) The Group's investments in equity securities comprise shares issued by domestic and foreign domestic companies. The prices of equity securities would change due to uncertainties in the future value of investee companies. If the prices of such equity instruments increase or decrease by 1%, with all other factors remain constant, the net profit after tax for the three months ended March 31, 2026 and 2025, would increase or decrease by $511 and $498, respectively, due to gains or losses from equity instruments measured at fair value through profit or loss; while other comprehensive income would increase or decrease of $3,185 and $2,496, respectively, due to gains or losses from equity investments classified as measured at FVOCI.

C. Cash flow and fair value interest rate risk

(A) The Group's main interest rate risk arises from long-term borrowings with variable rates. Borrowings issued at variable rates expose the Group to cash

flow interest rate risk. For the three months ended March 31, 2026 and 2025, the borrowings issued by the Group at floating rates were primarily denominated in New Taiwan Dollars.

(B) For the three months ended March 31, 2026 and 2025, if the borrowing interest rate changes by 1%, with all other factors held constant, profit, net of tax for the three months ended March 31, 2026 and 2025 would have decreased or increased by $2,004 and $1,382, respectively, mainly due to interest expense decrease or increase resulting from floating rate borrowings.

(ii) Credit risk

A. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations, mainly due to counterparties could not repay in full the accounts receivable based on the agreed terms.

B. The Group manages its credit risk with consideration of the Group as a whole. Following the internally defined credit policy, each operating entity within the Group is responsible for managing and analyzing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. The limits for individual risks are established by the Board of Directors based on internal or external ratings, and the utilization of credit limits is regularly monitored.

C. The Group adopts the assumptions under IFRS 9 that if the contract payments are more than 90 days past due based on the terms, it is considered as a default.

D. The Group adopts the following assumption under IFRS 9 to assess whether there is a substantial increase in credit risk on that instrument since initial recognition: If the contract payments are more than 30 days past due based on the terms, a substantial increase in credit risk is considered to exist on that instrument since initial recognition.

E. The following indicators are used to determine whether the credit impairment of debt instruments has occurred:

(A) It becomes probable that the issuer will enter bankruptcy or other financial reorganization due to their financial difficulties;

(B) The disappearance of an active market for that financial asset because of financial difficulties;

(C) Default or delinquency in interest or principal repayments;

(D) Adverse changes in national or regional economic conditions that are expected to cause a default.

F. The Group classifies customers' accounts receivable and contract assets in

accordance with customer types. The Group adopts a simplified approach and estimates expected credit losses based on individual assessments.

G. The Group's notes and accounts receivables (including related parties) and contract assets are mostly from customers with strong credit ratings, and the expected credit loss rate is 0.3% after taking into forward-looking economic considerations. As of March 31, 2026, December 31, 2025, and March 31, 2025, the total carrying amounts of the Group's notes receivable and accounts receivable (including related parties) were $42,874, $114,152 and $234,479, respectively. While certain accounts receivable were overdue by more than 90 days, the associated credit risk was assessed to be not significant. As of March 31, 2026, December 31, 2025, and March 31, 2025, the Group's contract assets amounted to $178,191, $171,144 and $302,105, respectively, with a loss allowance of $0 for all.

H. The Group calculates expected credit loss using individual assessment for customers with higher credit risk. As of March 31, 2026, December 31, 2025, and March 31, 2025, the total carrying amount of the Group's notes and accounts receivable (including related parties) from these customers were $24,315, $44,442 and $60,240, respectively, with a loss allowance of $24,315, $44,442 and $60,240, respectively. As of March 31, 2026, December 31, 2025, and March 31, 2025, the Group's contract assets for these customers amounted to $4,304, $4,304 and $14,277, respectively, with a loss allowance of $4,304, $4,304 and $14,277, respectively.

I. The changes in loss allowance for notes receivable, accounts receivable, and contract assets of the Group adopting a simplified approach are as follows:

	Three months ended March 31, 2026			
	Notes receivable	Accounts receivable	Contract assets	Total
January 1	$ -	$ 44,442	$ 4,304	$ 48,746
Provision for impairment	–	(20,127)	–	(20,127)
March 31	$ -	$ 24,315	$ 4,304	$ 28,619

	Three months ended March 31, 2025			
	Notes receivable	Accounts receivable	Contract assets	Total
January 1	$ -	$ 73,183	$ 14,751	$ 87,934
Provision for impairment	–	(12,943)	(474)	(13,417)
March 31	$ -	$ 60,240	$ 14,277	$ 74,517

J. The counterparties of the Group's investments in debt instrument measured at amortized cost have good credit quality, so the loss allowance measured based on 12 months expected credit losses is minimal.

(iii) Liquidity risk

A. Cash flow forecasts are prepared by individual operating entities of the Group and subsequently consolidated by the Group's Treasury. The Group's Treasury monitors rolling forecasts of the Group's liquidity requirements to ensure sufficient cash is available to meet operational needs.

B. Surplus cash held by individual operating entities, when exceeding the balance required for managing working capital, are transferred to the Group's Treasury. The Group's Treasury invests surplus cash in interest bearing current accounts and time deposits, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient headroom as determined by the abovementioned forecasts.

C. Details of the Group's undrawn borrowing facilities are as follows:

	March 31, 2026	December 31, 2025	March 31, 2025
Floating rate			
Expiring within one year	$ 1,460,000	$ 1,460,000	$ 1,650,000
Expiring beyond one year	1,443,380	1,562,000	1,754,290
	$ 2,903,380	$ 3,022,000	$ 3,404,290

D. The table below analyzes the Group's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

March 31, 2026	Within 1 year	1 to 5 years	Over 5 years	Total
Non-derivative financial liabilities:				
Accounts payable	169,496	–	–	169,496
Other payables	271,145	–	–	271,145
Other payables – related parties	12,129	–	–	12,129
Lease liabilities	31,669	116,570	570,229	718,468
Long-term borrowings	18,716	793,698	262,259	1,074,673
Guarantee deposits received (presented as "other non-current liabilities, others")	420	–	–	420

December 31, 2025	Within 1 year	1 to 5 years	Over 5 years	Total
Non-derivative financial liabilities:				
Short-term borrowings	$ 300,078	$ -	$ -	$ 300,078
Accounts payable	98,136	–	–	98,136
Accounts payable – related parties	1,722	–	–	1,722
Other payables	395,119	–	–	395,119
Other payables – related parties	12,448	–	–	12,448
Lease liabilities	32,350	116,798	577,675	726,823
Long-term borrowings	16,676	712,729	219,489	948,894
Guarantee deposits received (presented as "other non-current liabilities, others")	420	–	–	420

March 31, 2025	Within 1 year	1 to 5 years	Over 5 years	Total
Non-derivative financial liabilities:				
Accounts payable	$ 96,216	$ -	$ -	$ 96,216
Accounts payable – related parties	215	–	–	215
Other payables	427,737	–	–	427,737
Other payables – related parties	10,555	–	–	10,555
Lease liabilities	33,748	120,237	600,911	754,896
Long-term borrowings	10,845	594,093	142,679	747,617
Guarantee deposits received (presented as "other non-current liabilities, others")	420	–	–	420

E. The Group does not expect the timing of occurrence of the cash flows estimated through the maturity date analysis will be significantly earlier, nor expect the actual cash flow amount will be significantly different.

(3) Fair value information

i. The different levels of inputs used in valuation techniques to measure the fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access on the measurement date. An active market refers to a market in which transactions for an asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

Certain emerging stocks in which the Group has invested fall into this category.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Preferred shares in which the Group has invested fall into this category.

Level 3: Unobservable inputs for the asset or liability. Equity instruments that are not actively traded in which the Group has invested fall into this category.

ii. Financial instruments not measured at fair value

Except for financial assets at fair value through profit or loss and financial assets measured at FVOCI, the carrying amounts of cash and cash equivalents, financial assets at amortized cost, notes receivable, accounts receivable (including related parties), other receivables, guarantee deposits paid (presented as "other non-current assets"), short-term borrowings, accounts payable (including related parties), other payables (including related parties), long-term borrowings (including current portion), guarantee deposits received (presented as "other current liabilities, others" and "other non-current liabilities, others") and lease liabilities are approximate to their fair values.

iii. The related information on financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

(i) The related information on the nature of the assets and liabilities is as follows:

	March 31, 2026			
	Level 1	Level 2	Level 3	Total
Assets				
Recurring fair value measurements				
Financial assets at fair value through profit or loss				
Profit-sharing investment in new drug development	$ –	$ –	$ 63,990	$ 63,990
Limited partnership venture capital	–	–	51,120	51,120
Financial assets at FVOCI				
Equity securities	55,281	63,990	199,276	318,547
Total	$ 55,281	$ 63,990	$ 314,386	$ 433,657

	December 31, 2025			
	Level 1	Level 2	Level 3	Total
Assets				
Recurring fair value measurements				
Financial assets at fair value through profit or loss				
Profit-sharing investment in new drug development	$ –	$ –-	$ 62,860	$ 62,860
Limited partnership venture capital	–	–	52,118	52,118
Preferred shares	–	33,080	–	33,080
Financial assets at FVOCI				
Equity securities	49,523	31,470	209,893	290,886
Total	$ 49,523	$ 64,550	$ 324,871	$ 438,944

	March 31, 2025			
	Level 1	Level 2	Level 3	Total
Assets				
Recurring fair value measurements				
Financial assets at fair value through profit or loss				
Profit-sharing investment in new drug development	$ -	$ -	$ 66,410	$ 66,410
Limited partnership venture capital	–	–	49,800	49,800
Financial assets at FVOCI				
Equity securities	–	–	249,593	249,593
Total	$ -	$ -	$ 365,803	$ 365,803

(ii) The methods and assumptions used by the Group to measure fair value are described as follows:

A. For financial instruments where the Group uses market quotes as fair value inputs (i.e., Level 1), their characteristics are categorized as follows:

	Emerging and OTC stocks
Market quotation	Month-end average closing price

B. In addition to the aforementioned financial instruments with active markets, the fair value of the remaining financial instruments is obtained through valuation techniques or by reference to counterparty quotes. Fair value obtained through valuation techniques may be derived by reference to the current fair value of other

financial instruments with substantially similar conditions and characteristics, the discounted cash flow method, or other valuation techniques.

iv. The table below lists the changes in Level 3 for the three months ended March 31, 2026 and 2025:

	2026			
	Equity instruments	Profit-sharing investment in new drug development	Limited partnership venture capital	Total
January 1	$ 209,893	$ 62,860	$ 52,118	$ 324,871
Additions for the period	–	–	5,681	5,681
Gains or losses recognized in profit or loss				
Gains on valuation	–	1,130	(6,679)	(5,549)
Gains and losses recognized in other comprehensive income				
Losses on valuation	(10,617)	–	–	(10,617)
March 31	$ 199,276	$ 63,990	$ 51,120	$ 314,386

	2025			
	Equity instruments	Profit-sharing investment in new drug development	Limited partnership venture capital	Total
January 1	$ 263,125	$ 65,570	$ 36,572	$ 365,267
Additions for the period	–	–	15,000	15,000
Gains or losses recognized in profit or loss				
Valuation gain (loss)	–	840	(1,772)	(932)
Gains and losses recognized in other comprehensive income				
Losses on valuation	(13,532)	–	–	(13,532)
March 31	$ 249,593	$ 66,410	$ 49,800	$ 365,803

v. As the market trading volume of AP Biosciences Inc. has increased steadily starting from December 2025, resulting in the availability of sufficient quoted prices in an active market, the Group transferred its fair value measurement from Level 3 to Level 1 at the end of the month in which the event occurred. v. There were no transfers into or out of Level 3 during the three months ended March 31, 2026 and 2025.

vi. The Group's financial assets at fair value through profit or loss – preferred shares and certain financial assets measured through other comprehensive income are measured at fair value estimated by reference to the most recent transaction price in the market.

vii. The appointed external appraiser is responsible for the valuation procedures for fair value measurements being categorized within Level 3, and frequently calibrating valuation model, performing back-testing, updating inputs used in the valuation model and making any other necessary adjustments to the fair value to ensure the valuation results are reasonable.

viii. The quantitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement is as follows:

	Fair value as of March 31, 2026	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship between inputs and fair value
Non-derivative equity instrument:					
Non-listed shares	$ 7,805	Price-to-book ratio method	Price-to-book ratio	2.61 (2.61)	The higher the multiple, the higher the fair value
			Liquidity discount	30% (30%)	The higher the discount for lack of marketability, the lower the fair value
Emerging stocks	191,471	Price-to-book ratio method	Price-to-book ratio	1.62 (1.62)	The higher the multiple, the higher the fair value
			Liquidity discount	17.38% (17.38%)	The higher the discount for lack of marketability, the lower the fair value
Profit-sharing investment in new drug development	63,990	Royalty savings method of income approach	Discount rate	27.98%	The higher the discount rate, the lower the fair value
			Market share	1.9%–5.6%	The higher the market share, the higher the fair value
Limited partnership venture capital	51,120	Net asset value method	N/A	N/A	N/A

	Fair value as of December 31, 2025	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship between inputs and fair value
Non-derivative equity instrument:					
Non-listed shares	$ 7,845	Price-to-book ratio method	Price-to-book ratio	2.61 (2.61)	The higher the multiple, the higher the fair value
			Liquidity discount	30% (30%)	The higher the discount for lack of marketability, the lower the fair value
Emerging stocks	202,048	Price-to-book ratio method	Price-to-book ratio	1.67 (1.67)	The higher the multiple, the higher the fair value
			Liquidity discount	16.59% (16.59%)	The higher the discount for lack of marketability, the lower the fair value
Profit-sharing investment in new drug development	62,860	Royalty savings method of income approach	Discount rate	26.56%	The higher the discount rate, the lower the fair value
			Market share	1.9%–5.6%	The higher the market share, the higher the fair value
Limited partnership venture capital	52,118	Net asset value method	N/A	N/A	N/A

	Fair value as of March 31, 2025	Valuation technique	Significant unobservable input	Range (weighted average)	Relationship between inputs and fair value
Non-derivative equity instrument:					
Non-listed shares	$ 8,714	Price-to-book ratio method	Price-to-book ratio	2.61 (2.61)	The higher the multiple, the higher the fair value
			Liquidity discount	30% (30%)	The higher the discount for lack of marketability, the lower the fair value
Emerging and non-listed shares	215,689	Price-to-book ratio method	Price-to-book ratio	1.40 (1.40)	The higher the multiple, the higher the fair value
			Liquidity discount	11.05% (11.05%)	The higher the discount for lack of marketability, the lower the fair value
Profit-sharing investment in new drug development	66,410	Royalty savings method of income approach	Discount rate	26.03%	The higher the discount rate, the lower the fair value
			Market share	2.0%–5.9%	The higher the market share, the higher the fair value
Limited partnership venture capital	49,800	Net asset value method	N/A	N/A	N/A
Emerging and non-listed shares	25,190	Price-to-book ratio method	Price-to-book ratio	3.77 (3.77)	The higher the multiple, the higher the fair value
			Liquidity discount	30.00% (30.00%)	The higher the discount for lack of marketability, the lower the fair value

ix. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurements. The effects on profit or loss or on other comprehensive income from financial assets and liabilities categorized within Level 3 if the inputs used to valuation models were to change are as follows:

			March 31, 2026			
			Recognized in profit or loss		Recognized in other comprehensive income	
	Input value	Fluctuation	Favorable changes	Adverse changes	Favorable changes	Adverse changes
Financial assets						
Profit-sharing investment in new drug development	Discount rate Market share	±5%	$ 3,200	($ 3,200)	$ -	$ -
Limited partnership venture capital	N/A	±5%	2,556	($ 2,556)	–	–
Emerging and non-listed shares	Price-to-book ratio	±5%	–	–	9,964	(9,964)
	Lack of marketability	±5%	–	–	9,964	(9,964)
Total			$ 5,756	($ 5,756)	$ 19,928	($ 19,928)

			December 31, 2025			
			Recognized in profit or loss		Recognized in other comprehensive income	
	Input value	Fluctuation	Favorable changes	Adverse changes	Favorable changes	Adverse changes
Financial assets						
Profit-sharing investment in new drug development	Discount rate Market share	±5%	$ 3,143	($ 3,143)	$ -	$ -
Limited partnership venture capital	N/A	±5%	2,606	($ 2,606)	–	–
Emerging and non-listed shares	Price-to-book ratio	±5%	–	–	10,495	(10,495)
	Lack of marketability	±5%	–	–	10,495	(10,495)
Total			$ 5,749	($ 5,749)	$ 20,990	($ 20,990)

			March 31, 2025			
			Recognized in profit or loss		Recognized in other comprehensive income	
	Input value	Fluctuation	Favorable changes	Adverse changes	Favorable changes	Adverse changes
Financial assets						
Profit-sharing investment in new drug development	Discount rate Market share	±5%	$ 3,321	($ 3,321)	$ -	$ -
Limited partnership venture capital	N/A	±5%	2,490	($ 2,490)	–	–
Emerging and non-listed shares	Price-to-book ratio	±5%	–	–	12,480	(12,480)
	Lack of marketability	±5%	–	–	12,480	(12,480)
Total			$ 5,811	($ 5,811)	$ 24,960	($ 24,960)

13. Supplementary Disclosures

(1) Significant transactions information

i. Loans to others: None.

ii. Provision of endorsements and guarantees to others: None.

iii. Significant marketable securities held at end of period (excluding investment in subsidiaries, associates, and joint ventures): Please refer to Appendix 1.

iv. Total Purchases from or sales to related parties amounting to at least NT$100 million or 20% of paid-in capital: None.

v. Receivables from related parties amounting to at least NT$100 million or 20% of paid-in capital: None.

vi. Intercompany business relationships and material transactions: Please refer to Appendix 2.

(2) Information on investees

Names, locations and other information of investee companies (excluding investees in Mainland China): Please refer to Appendix 3.

(3) Information on investments in mainland China

None.

14. Segment Information

(1) General information

The Group is primarily engaged in the research and development (R&D) of biosimilars and new drugs, along with biopharmaceutical contract development and manufacturing services, including cell line construction platforms, process development platforms, analytical science and protein identification, as well as PIC/S GMP facilities to provide production of clinical trial drug and commercial drug products, etc. The Group operates within a single industry. The Group operates within a single industry. In addition, the Group's chief operating decision maker allocates resources and assesses performance of the Group as a whole, has identified that the Group has only one reportable segment.

(2) Segment Information

The accounting policies of the operating segment are consistent with those stated in the Summary of Key Accounting Policies in Note 4 to the Consolidated Financial Statements for 2025. The Group's segment profit or loss is measured with net profit (loss) before tax, which serves as a basis for the Group in assessing the performance of the operating segment.

(3) Information about segment profit or loss, assets, and liabilities

The Group has only one reportable segment; thus, the reportable information is in agreement with those presented in the 2025 Consolidated Financial Statements.

(4) Information on segment profit or loss adjustments

The amounts provided to the chief operating decision maker with respect to segment assets, liabilities and net profit (loss) before tax from continuing operations are measured in a manner consistent with the income and expenses stated in the consolidated balance sheet and consolidated statement of comprehensive income. Therefore, no reconciliation is required.

EIRGENIX INC. AND SUBSIDIARIES

SIGNIFICANT SECURITIES HELD AT END OF PERIOD (EXCLUDING INVESTMENT IN SUBSIDIARIES, ASSOCIATES, AND JOINT VENTURES)

March 31, 2026

Appendix 1

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

				End of period				
Holder	Type and name of securities	Relationship	Accounting item	No. of shares	Carrying amount	Shareholding (%)	Fair value	Note
EirGenix Inc.	Ordinary shares, AP Biosciences Inc.	None	Non-current financial assets at FVOCI	277,000	$ 55,281	0.33%	$ 55,281	
"	Ordinary shares, TFBS Bioscience Inc.	The Company's other related party	"	4,942,455	191,471	13.96%	191,471	
	Preferred shares, Valere Holding LLC	None	"	1,446,853	63,990	-	63,990	
"	Equity, Forward BioT Venture Capital	"	Non-current financial assets at fair value through profit or loss	-	45,506	5.60%	45,506	
"	Government bonds, 93 Central Government Bonds A6	"	Non-current financial assets at amortized cost	-	30,727	-	-	
"	Nomura International Funding Pte Ltd 7% Ann 09/12/31(Nc09/12/25)	"	"	-	47,992	-	-	
"	Nomura International Funding Pte Ltd 6.5% Ann 10/07/31(Nc10/07/25,10/07/26 Rst3.25%)	"	"	-	31,995	-	-	
"	Credit Agricole Corporate & 6.5% ANN 03/28/32(Nc03/28/26,Rst3.2%)	"	"	-	31,995	-	-	

Note: Individual amounts less than $30,000 are not disclosed.

EIRGENIX INC. AND SUBSIDIARIES

BUSINESS RELATIONSHIPS AND SIGNIFICANT TRANSACTION DETAILS BETWEEN THE PARENT AND ITS SUBSIDIARIES

January 1 to March 31, 2026

Appendix 2

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

Code (Note 1)	Company name	Counterparty	Relationship (Note 2)	Transaction details				Percentage of consolidated total operating revenue or total assets (Note 3)
				Accounting item		Amount	Transaction terms	
0	EirGenix Inc.	EirGenix Europe GmbH	(1)	Operating expenses	$	20,519	Note 4	6.65%

Note 1: The business transaction information between the parent company and its subsidiaries shall be specified separately in the numbering column. The numbering method is as follows:

(1) Parent company is "0".

(2) Subsidiaries are sequentially numbered starting from "1".

Note 2: The relationship between transaction company and counterparty is classified into the following three categories; the number for the category each case belongs to is filled in (if transactions between the parent company and its subsidiaries or between subsidiaries refer to the same transaction, it is not required to disclose twice. For example: For a transaction between the parent company and its subsidiary, if the parent company has already disclosed the transaction, the subsidiary is not required to disclose it again; for a transaction between two subsidiaries, if one subsidiary has already disclosed the transaction, then the other one is not required to disclose it again):

(1) Parent company to subsidiary.

(2) Subsidiary to parent company.

(3) Subsidiary to subsidiary.

Note 3: The percentage of transaction amount to consolidated total operating revenue or total assets is computed based on the percentage of period-end balance of transaction to consolidated total assets for balance sheet account items, and based on the percentage of accumulated transaction amount for the period to consolidated total operating revenue for income statement account items.

Note 4: Prices and terms for services are based on the mutual agreement and payments are collected quarterly in advance.

Note 5: Material transactions between the parent company and its subsidiaries are eliminated.

Note 6: Individual amounts less than $10,000 are not disclosed.

EIRGENIX INC. AND SUBSIDIARIES

NAMES, LOCATIONS AND OTHER INFORMATION OF INVESTEE COMPANIES (EXCLUDING INVESTEES IN MAINLAND CHINA)

January 1 to March 31, 2026

Appendix 3

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

Investor	Investee	Location	Main business activities	Initial investment amount		Held at end of period			Net income (loss) of investee for the period	Investment income (loss) recognized for the period	Note
				End of period	End of last year	No. of shares	Shareholding (%)	Carrying amount			
EirGenix Inc.	EirGenix Europe GmbH	Germany	Biopharmaceutical R&D and business development	$ 3,695	$ 3,324	–	100.00%	$ 15,125	$ 705	$ 705	None
EirGenix Inc.	EirGenix USA Inc.	USA	Biopharmaceutical commissioned development, manufacturing services, and consultation	3	3	10,000,000	100.00%	534	66	66	None